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Ellagic acid (EA) is a polyphenol found in various fruits and plants, such as 
berries, pomegranates, muscadine grapes, nuts and bark of oak tree. EA has been known 
to exhibit anti-inflammatory and anti-proliferative effects in various types of cancer. 
However, little is known about the effects of EA on obesity. Herein, 1) the lipid-lowering 
role of EA was identified in primary human adipose stem cells (hASCs) and human 
hepatoma Huh7 cells; 2) the molecular mechanisms by which EA attenuates adipogenesis 
by epigenetic modification were identified; 3) the effects of EA on high fat and high 
sucrose-mediated obesity was determined in young C57BL/6J mice; and 4) the potential 
role of urolithins (Uro), metabolites of EA, in attenuating adipogenesis and lipogenesis of 
adipocytes were investigated. 
In this dissertation research, I firstly identified the novel inhibitory roles of EA on 
hypertrophic (increase in fat cell size) or hyperplastic (new fat cell formation) adipocyte 
expansion. 10 M of EA treatment significantly repressed hypertrophic lipid 
accumulation by inhibiting de novo lipogenesis of fatty acid in mature adipocytes. The 
anti-lipogenic effects of EA was also confirmed in Huh7 cells. EA were able to reverse 
the exogenous fatty acid-induced hepatic triglyceride (TG) accumulation by increasing -
oxidation. These results suggested that EA exerts TG-lowering effects both in adipose 
tissue and liver. Intriguingly, EA were also able to repress adipogenic conversion of 
hASCs by blocking early adipogenic markers. Since epigenetic modification has been 
recently revealed to be a key mechanism regulating adipocyte differentiation, chromatin 
modifying enzymes were measured. Inhibition of adipogenic conversion of EA was 
accompanied with augmentation of histone deacetylase (HDAC) 9 and reduction of 
histone methyltransferase (coactivator associated arginine methyltransferase 1, CARM1) 
activity. Next, we confirmed lipid-lowering effects of EA in vivo. High fat and high 
sucrose diet for 12 weeks resulted in a significantly increase in; 1) body weight, 2) 
plasma cholesterol and TG levels, 3) hepatic endoplasmic reticulum (ER)/oxidative stress, 
and 4) adipose inflammation, which were normalized by EA-containing raspberry seed 
flour (RSF) supplementation without altering food intake. Furthermore, systemic levels 
of glucose and insulin tolerance and hepatic insulin sensitivity were improved by RSF. 
Finally, to determine whether Uro, gut microbiota-derived metabolites from of EA, 
displays anti-adipogenic and anti-lipogenic effects of EA in adipocytes, UroA, B, C, D, 
and iso-UroA were added to differentiating and differentiated hASCs. UroA, C and D are 
biologically active gut metabolites of EA exerting potent lipid-lowering effects in 
adipocyte similar to EA. Overall, these data suggest that EA is a potent dietary factor to 
attenuate obesity and Uro may be novel metabolites manifesting EA’s effects.  
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I. INTRODUCTION: REVIEW LITERATURES 
Obesity has reached epidemic proportions in the United States and worldwide [1, 
2]. A systemic analysis for Global Burden of Disease Study reported that the prevalence 
of obesity has increased from ~30 % to 40 % during 1980-2013 worldwide underlining 
the urgent need of global action to intervene obesity [3].  The major cause of obesity is 
likely attributed to the obesogenic diets, although other factors such as lack of exercise, 
unhealthy eating habits, and genetic preposition expedite the onset of obesity and/or 
exacerbate severity of obesity [4]. Obesity develops from chronic positive energy 
imbalance when food intake exceeds the energy expenditure [5]. The progression of 
obesity is initiated by adipose tissue expansion by depositing surplus energy into the form 
of triglyceride (TG). Adipose tissue expansion occurs by forming new fat cell formation 
(hyperplasia, adipogenesis) or by enlarging its size to aggrandize TG storage capacity 
(hypertrophy) [6]. Several studies have clearly demonstrated that high fat (HF) diet 
triggers visceral fat expansion through adipocyte hyperplasia as well as adipocyte 
hypertrophy [7]. The increased visceral adiposity is accompanied by an increase of 
immune cell infilatration into adipose tissue,  basal (or non-stimulatory) lipolyis, and 
defective adipokine secetion [6, 8]. These immunological and endocrinological changes 
of adipose tissue during pathogenesis of obesity are positively associated with hepatic 
steatosis and systemic levels of glucose intolerance and insulin resistance (Figure I-1) [9, 
10]. Thus, there is an imminent need to devise dietary regimens to disconnect the viscious 
link between diet-induced adipocyte expansion and metabolic dysfunction. 
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Figure I-1 Schematic diagram showing that factors affect the pathogenesis of 
obesity. Obesity is accompanied by oxidative stress, inflammation, and dyslipidemia, 
which synergistically progress to obesity-related diseases, type 2 diabetes and NAFLD. 
 
The increased intake of fruits and vegetables (FV) has been shown to inversely 
correlate with inidence of obesity [11, 12]. In addition to the benefits from fiber 
consumption, dietary polyphenolic compounds in FV have attracted attention due to its 
biochemical ability to modulate signaling pathways of lipid and glucose metabolism. 
Among numerous polyphenolic compounds, we and others have recently recognized that 
ellagic acid (EA), abundant polyphenolic compound found in various berries and nuts, as 
one of promising dietary candidate to control obesity and its associated metabolic 
complications.  Besides to its anti-proliferative function of EA in cancer, there is 
accumulating evidence that EA decreases chronic metabolic diseases such as 
dyslipidemia, insulin resistance and non-alcoholic fatty liver diseases. This review 
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comprised of three sections to provide a novel insight into 1) bioavailability of EA, 2) in 
vitro and in vivo evidence that EA is capable to regulate lipid and glucose metabolism, 
and 3) mode of action that EA counteracts obesity-associated metabolic diseases. 
According to literature search in NCBI Pubmed on July 2015, 1,721 articles have been 
published regarding EA since 1964 (Figure I-2). However, the molecular mechanisms by 
which EA exerts anti-obesogenic effects by modulating lipid and glucose metabolisms 
remain unclear.   
 
Figure I-2 Yearly number of publications related to EA from 1964-2015. Data were 
obtained from PubMed. Data for the year 2015 shows the numbers of publications 
available up through July 31, 2015. 
 
In this review, I thoroughly discuss the emerging evidence that EA alters gene 
expression, cell signaling, and metabolism to reduce overweight and obesity in vitro and 
in vivo. I also comprehensively review the molecular mechanisms by which dietary EA 
attenuates obesity driven-health abnormality, and propose dietary EA as a promising 
polyphenolic compound to combat obesity.  
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Bioavailability of EA 
EA (2,3,7,8-tetrahydroxy [1]-benzopyranol [5,4,3-cde]benzopyran-5,10-dion) was 
firstly discovered by Braconnot in 1831 [13]. EA is a highly thermostable molecule 
(melting point 350 
°
C), with molecular weight of 302.194 g mol
-1
. EA  consists of the 
lipophilic part with four rings and the hydrophilic part with four hydroxyl group and two 
lactone groups [14]. The strong hydrogen-bonding network act as an electron acceptor, 
which in turn enables EA to participate in a number of reactions [15]. EA is naturally 
present in numerous fruits and vegetables including strawberries, blackberries, red and 
black raspberries, and nuts including walnuts, pistachio, cashew nuts, oak acorns and 
pecans [16, 17] in the form of hydrolysable ellagitannins (ETs). ETs are also abundant in 
pomegranates and muscadine grapes especially in seed and skin [18-20]. Following oral 
administration of EA-containing foods, ET is hydrolyzed to form free EA. Subsequently, 
majority of EA undergoes metabolic converion by intestinal gut microbes resulting in 
generation of urolithins (Uro, dibenzopyran-6-one metabolites) through reduction of one 
of the two lactone groups and decarboxylation and dihydroxylation (UroD  UroC  
UroA or iso-UroA  UroB) (Figure I-3) [21]. Besides its microbial conversion into Uro, 
free EA undergoes phases II reactions that are conjugation processes of glucuronidation, 
sulfation and methylation at the large intestine. In physiological condition, virtually very 
low EA can be found in plasma or tissues based on human clinical trials [22] as well as  
on studies with rodents and other small mammals [23, 24]. More specifically, upon 
ingestion, peak plasma concentration of free EA is no more than 100 nM in plasma. 
However, Uro and its conjugated form can reach micromolar concentrations in plasma 
[25]. Furthermore, EA is found only a trace amount in the peripheral tissues, whereas Uro 
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and its conjugates accumulate in the prostate, intestine, and colon [26]. Glucuronides and 
methyl glucuronide of EA, UroA, and UroD present in the bile through enterohepatic 
circulation [27]. Phase II reactions of EA also affect EA uptake in hepatocytes and 
additional metabolism in liver [28]. However, specific bacterial strains that convert EA or 
its intermediate metabolites into UroA, B and D have not been identified yet.  
Likewise to the many other polyphenolic compounds, low bioavailability is the 
major limiting factor for dietary EA to exhibit metabolic activities in vivo. Noticeably, 
however, the most recent study by González-Sarrías et al. reports that EA could be found 
higher concentration than previously reported [29]. Apparently bioavailability of EA is 
regulated by multiple factors including conjugation with tannin, microbial conversion 
into Uro, metabolism in hepatocytes, and phase II reaction. Nonetheless of these limited 
bioavailability, pure EA or EA-containing food seem to effective in normalizing obesity 
and obesity-mediated metabolic dysfunction as we summarize in following sections.  
 
  
Figure I-3 Chemical structures of EA and Uro. A series of metabolites called 
“Urolithins” are formed from EA via enzymatic activation of gut microbes.  
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Effects of EA on obesity 
In vitro evidence 
There are several studies having directly or indirectly investigated the potential 
role of EA in adiposity control using adipocyte cell models (Table I-1). The most 
popular cell used to identify the anti-adipogenic effects is 3T3-L1 cell, a well-established 
murine pre-adipocyte cell line. Using 3T3-L1 cells, Mejia-Meza et al. first reported that 
EA-containing food alter adipocyte differentiation [30]. In their study, it is demonstrated 
that 250 μg/mL of fresh and dried red raspberries, which contain a large amount of EA 
(around 3.7 mg/g dry basis) as well as other polyphenolic compounds, inhibit 
adipogenesis and reduces lipid accumulation in 3T3-L1 cells. Wang et al. found that 15-
20 M of the concentration of EA significantly reduced adipogenesis through inhibition 
of cell cycle progression from G1S transition without causing apoptosis in 3T3-L1 
cells [31]. Consistently, Woo et al. also demonstrated EA significantly reduced lipid 
accumulation and early adipogenic markers such as kruppel-like factor 4 (KLF4), KLF5, 
Krox20 as well as peroxisome proliferator-activated receptor  (PPAR), and 
CCAAT/enhancer binding protein  (C/EBP)via cell cycle arrest [32]. These initial 
results that EA decreases adipocyte differentiation in 3T3-L1 cells were confirmed and 
obtained human relevance by the following studies from primary cultures of human 
adipocytes. Primary human adipogenic stem cells (hASCs), isolated from scavenged 
adipose tissue after liposuction or abdominoplasty surgery [33], have been extensively 
used to investigate adipocyte lipid metabolism in humans. Okla et al. [34] reported that 
muscadine grape polyphenols (MGP), which contains 18.2 mg/g of free EA were able to 
reduce lipid accumulation during adipogenesis in hASCs. Among the polyphenolic 
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constituents of MGP, authors identified that EA (~10 M) was the responsible 
polyphenol that exclusively represses the adipogenesis by decreased the expression of 
adipogenic genes, i.e., PPAR, fatty acid synthase (Fas), adipocyte protein 2 (aP2), and 
C/EBP [34, 35]. 
 Most in vitro studies were focused on investigating the role of EA in inhibiting 
new fat cell formation and few studies investigate the role of EA on terminal stage of 
differentiation or lipogenesis. Interestingly, Okla et al. showed that 3 day incubation of 
EA (10 M) in cultures of mature human adipocytes effectively reduces lipogenesis as 
well as in human hepatocytes. By using the radiolabeled precursor, it has been 
demonstrated that EA significantly reduced de novo lipogenesis, TG esterification, while 
enhanced FA oxidation. These TG-lipid lowering effects of MGP supplementation were 
confirmed in HF-fed C57BL mice showing that both hepatic TG contents and adipose 
tissue mass are reduced. The reduction of TG in liver was associated with increased 
hepatic FA oxidative gene expressions [34] implicating that decreased TG accumulation 
is linked with energy expenditure.  The activation of AMP-activated kinase (AMPK) is 
likely involved in this link, since AMPK activation has shown to regulate energy 
homeostasis [36] by inhibiting adipogenesis, de novo TG synthesis, and by augmenting 
FA oxidation [37]. Supporting this notion, Poulose et al. demonstrated that only 100 nM 
EA treatment for 30 minutes induced AMPK activation in fully differentiated 3T3-L1 
cells [38]. Consistently, Kang et al also showed that activation of AMPK is triggered by 
EA and UroA, C, and D in primary cultured of human adipocytes inhibiting 
differentiation of hASC into adipocytes (under review). Therefore, further analysis is 
required to validate these possibilities.  
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In addition to anti-adipogenic/lipogenic effects of EA, Chinese sweet leaf tea 
extract containing 10 g/ml of EA attenuated angiogenic gene expression of vascular 
endothelial growth factor (VEGF) in 3T3-L1 [39]. Another studies reported that EA 
containing pomegranate fruit extract (10-100 g/ml of EA) or pure EA (20-70 M) 
treatment in 3T3-L1 cells reduce resistin release, an anti-insulin sensitizing adipokine 
[40]. There are also another set of evidence that EA not only affects TG metabolism in 
adipocyte and hepatocytes, but also regulate cholesterol metabolism in macrophages. In 
J774A macrophage cell line, treatment of 5 M of EA for 18 hours showed reduced 
cholesterol ester (CE) accumulation by presumably reduced scavenger receptor class B 
member 1 (SR-B1) induction for oxLDL uptake, but increased cholesterol efflux [41].  
This study implicates that EA may be involved in reverse cholesterol transport process 
from the plaque area for attenuation of cardiovascular diseases risk.   
In vivo evidence 
The TG-lowering function of EA observed in in vitro studies is well supported by 
animal studies establishing physiological role of EA against the pathogenesis of obesity. 
A general consensus has found that EA-containing foods are effective in attenuating 
adiposity, plasma markers of metabolic syndrome although the attenuated fat mass were 
variable depending on the source and content of EA as well as supplementation duration 
(Table I-2). The dietary supplementation studies using ‘EA-containing whole foods’ 
such as pomegranate peel extract (6 mg EA/kg BW) [42], blueberry extracts  (150 mg of 
EA/kg BW) [43], Chinese sweet leaf tea  (220 mg EA/kg BW) [39], mango (1 or 10 % in 
diet) [44] and chestnut inner shell extract (150 mg/kg BW) [45], significantly reduced 
body weight as well as white adipose tissue mass in rodents. Moreover, despite same BW 
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changes, loss of visceral fat mass were found in some study such as 0.4% of MGP 
supplementation in C57BL/6 mice [18] and 30 mg/kg BW of Pomegranate fruit extract 
(PFE)-fed ovariectomized ddY female mice [40]. Pomegranate flower at a concentration 
of 0.5% in the diet was also able to reduce epididymal fat mass in aged ddY mice [46]. 
The loss of body weight and/or fat mass are accompanied by the improvement of plasma 
lipid profiles (reduced elevated FFA, TG, total cholesterol (TC), LDL, VLDL but 
increased HDL) and glycemic index (reduced hyperglycemia and hyperinsulinemia).  
Instead of EA-containing whole foods, it is also showed that “pure EA” is also 
able to attenuate obesity or obesity-mediated metabolic complications in animals. 
Furthermore, supplementation of 0.1% EA in KK-Ay mice, a type 2 diabetes mice model, 
ameliorated dysregulation of serum lipid profiles and resistin, and upregulated 
apolipoprotein A-I (ApoA-1), lipoprotein receptor (LDLr), carnitine palmitoyltransferase 
(CPT), and PPAR gene expressions in hepatic tissue resulting in improved hepatic 
steatosis [47]. Panchal et al. and Kannan et al. showed that EA (0.8 g/kg diet and 15 
mg/kg BW respectively) not only ameliorates lipid and  glucose metabolisms but also 
attenuates obesity-associated myocardiac dysfunction and cardiovascular remodeling by 
altered myocardial necrosis and upregulation of nuclear factor erythroid 2–related factor 
2 (Nrf2) and CPT1 expressions in heart and liver [48, 49]. Ahad et al. demonstrated that 
low-dose streptozotocin (STZ) injection with HF-diet triggered the diabetic nephropathy 
in Wistar albino rats, which was significantly prevented by oral administration of EA (40 
mg/kg BW for 16 weeks) attenuating dyslipidemia and onset of diabetic nephropathy [50] 
presumably through inactivation of renal nuclear factor-kappaB (NF-B) activation. 
Collectively, these studies suggest that EA may be beneficial to diabetes-associated 
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microvascular diseases such as cardiovascular diseases and diabetic kidney by decreasing 
chronic inflammation.  
In our effort to obtain a general impact of EA supplementation against 
pathogenesis of obesity, we conducted small meta-analysis using published data from 10 
animal studies with EA supplementation (Table I-3). It is noticeable that experimental 
groups with EA consumption reduced approximately 25% of dyslipidemia (decreased in 
TG) without altering food intake. The improvement of plasma lipid profile was more 
evident than measurable differences in total BW and/or adipose tissue mass. It might be 
attributed to the variable EA bioavailability depending on the source of EA. Further 
research is warranted whether intake of EA with other phytochemicals facilitates the EA 
uptake at the intestinal epithelium barrier. Moreover, future studies to determine 
appropriate dose of EA and the upper limit of safety as well as the underlying 
mechanisms of toxicity are necessary. 
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Table I-1  In vitro studies carried out with plant extracts rich in EA in relation to obesity and its metabolic complication 
Test material Test model  Dose/Duration Cell responses 
Physiological 
effects 
References 
EA 
3T3-L1 
preadipocytes 
5,25, and 50 
M, 6-8 days 
↓ lipid accumulation, PPAR, C/EBP,  
↓ early adipogenic markers KLF4, KLF5, Krox20, 
C/EBP within 24 hours 
Anti-adipogenesis 
Woo et al. 
(2015) 
EA 
Human liver cell 
line Huh7 cells 
10 M, 2 days 
↓ de novo TG synthesis and TG esterification,  
↑ FA oxidation 
Anti-lipogenesis 
Okla and Kang 
et al. (2015) 
EA 
Differentiated 
hASCs 
10 M, 3 or 7 
days 
Inhibits de novo lipogenesis Anti-lipogenesis 
Okla and Kang 
et al. (2015) 
EA hASCs 10 M, 7 days 
↓ adipogenic genes and protein (PPAR, C/EBP, 
aP2, Fas),  
alters epigenetic markers (↑HDAC9, ↓CARM1 
enzyme activity) 
Anti-adipogenesis 
Kang et al. 
(2014) 
EA 
3T3-L1 
preadipocytes 
20 M, 2 days 
↓ early day 2–4 of differentiation,  
↓ clonal expansion,  
block the cell cycle at the G1/S transition and 
Cyclin A  and Rb phosphorylation 
Anti-adipogenesis 
Wang et al. 
(2013) 
EA 
Macrophage-like 
cell line J774A1 
with oxidized LDL 
5 M, 18 hours 
↓ lipid accumulation and SR-B1 induction,  
↓ macrophage lipid uptake to block foam cells and 
↑ cholesterol efflux 
Anti-atherogenesis 
Park et atl. 
(2011) 
Chinese sweet leaf 
tea extract (GER) 
3T3-L1 
preadipocytes 
10 g/ml of 
GER 
↓ the expression of VEGF Anti-angiogenesis 
Koh et al. 
(2011) 
3,3'-di-O-
methylellagic acid 
and EA 
 3T3-L1 adipocytes 1,3,10 M ↓ TG, and GPDH activity Anti-adipogenesis 
Yang et al. 
(2011) 
Pomegranate fruit 
extract and EA 
3T3-L1 
preadipocytes 
10-100 g/ml 
of PFE, 20-70 
M of EA 
↓ resistin release 
Degradation of 
intracellular resistin 
Makino-
Wakagi et al. 
(2012) 
Abbreviation: EA, ellagic acid; PPARg, Peroxisome proliferator-activated receptor gamma; C/EBPa, CCAAT/enhancer binding protein alpha; KLF4, 
Kruppel-like factor 4; TG, triglyceride; hASCs, human adipogenic stem cells, Fas, Fatty acid synthetase; HDAC9, histone deacetylase 9; CARM1, co-
activator arginine methyltransferase 1; SR-B1, Scavenger receptor class B member 1; VEGF, Vascular endothelial growth factor; GPDH, Glycerol-3-
phosphate dehydrogenase 
1
2
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Table I-2 In vivo studies carried out using EA or EA-containing plants in relation to obesity and its metabolic complications 
Test material Test model  Dose/Duration 
Results 
Physiological 
effects 
References 
∆BW ∆Fat Cell responses 
EA 
HFD+STZ induced 
type 2 diabetic 
Wistar albino rats 
EA (40 mg/kg 
BW/day) for 16 
weeks 
- - 
-↓levels of TC, LDL-C, VLDL-C, 
FFA and TG,  
-↑ the levels of HDL-C 
Protection of 
diabetic 
nephropathy 
Ahad et al 
(2014) 
EA 
albino 
Wistar+isoproterenol 
(oxidative stress) 
EA (7.5 and 
15mg/kg BW) 
orally for 10 
days 
- - 
-Restores arrhythmias, ventricular 
hypertrophy, lipid peroxidation,  
-Altered lipid profile and 
myocardial necrosis 
Prevention of 
myocardial 
infarction 
Kannan et al. 
(2013) 
Chinese sweet 
leaf tea extract 
(GER) 
HFD fed male SD 
rats 
0.22g/kg BW, 
12weeks 
↓ ↓ 
-↓ glucose, TG, and cholesterol 
levels in blood 
Improvement of 
Obesity Phenotype 
Koh et al. 
(2011) 
Nanoparticle 
containing EA 
and coenzyme 
Q10 
HFD fed male SD 
rats 
10% (w/w of 
polymer), 2 
weeks 
- - 
-↓ glucose and hyperlipidemic 
conditions, 
-↑endothelial functioning 
Ameliorates 
hyperlipidemia 
Ratnam et al. 
(2009) 
EA 
HFD fed KKAy 
mice 
0.1% of EA in 
diet, 68 days 
- - 
-↓ serum resistin and  
-↓ hepatic steatosis and serum lipid 
profile,  
-↑ ApoA1, LDLr, CPT1, and 
PPAR genes in the liver 
Improves hepatic 
steatosis 
Yoshimura et al. 
(2013) 
Pomegranate 
fruit extract  
Female ddY mice 
(ovariectomized) 
30mg/kg BW, 
12weeks 
- ↓ -↓  serum TC levels 
Degradation of 
intracellular 
resistin 
Makino-Wakagi 
et al. (2012) 
Pomegranate 
leaf extract 
(PLE) 
HFD fed ICR mice 
400 or 
800mg/kg BW 
of PLE, 5 weeks 
↓ ↓ - improves lipid profiles Anti-obesity Let et al. (2007) 
 
  
1
3
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Table I-2 (continued) 
Test material Test model  Dose/Duration 
Results 
Physiological 
effects 
References 
∆BW ∆Fat Cell responses 
EA HFHC fed wistar rat 
 0.8 g/kg of 
BW, 16 weeks 
↓ ↓ 
-Improves cardiovascular 
remodeling,  ventricular function,  
glucose tolerance, non-alcoholic 
fatty liver disease,  
-↑ Nrf2, and CPT1 in heart and liver 
Attenuates high-
carbohydrate, 
high-fat diet-
induced metabolic 
syndrome 
Panchal et al. 
(2013) 
Muscadine grape 
phytochemicals 
(MGP) 
HFD fed C57BL/6J 
mice 
0.4% of MGP in 
diet, 15 weeks 
- ↓ 
-Improves glucose, insulin FFA, 
TG, TC and CRP in plasma 
anti-obesity and 
metabolic 
complications 
Gourineni et al. 
(2012) 
Hydro-alcoholic 
fruit extract of 
avocado (HFEA) 
HFD fed SD rats 
100 mg/kg BW 
of HFEA, 11 
weeks 
↓ ↓ 
-↓ TG, TC,  LDL and leptin in 
plasma, 
↓ FASN, LPL, and leptin while ↑ 
FGF21  gene expressions in WAT 
Hypolipidemic 
effect  
Monika et al. 
(2015) 
Abbreviation: EA, ellagic acid; wk, week; HFD, high fat diet; STZ, streptozotocin; TC, total cholesterol; LDL-C, low density lipoprotein-cholesterol; 
VLDL-C, very low density lipoprotein; FFA, free fatty acid; TG, triglyceride; HDL-C, high density lipoprotein-cholesterol; SD, Sprague Dawley; BW, 
body weight; ApoA1,Apolipoprotein A-I; LDLr, LDL receptor; CPT1, Carnitine palmitoyltransferase I; PPAR, Peroxisome proliferator-activated receptor 
gamma; FI, food intake; WAT, white adipose tissue; Nrf2, nuclear factor erythroid 2–related factor 2; NF-kB, Nuclear factor kappa B; HFHC, high fat and 
high carbohydrate; CRP, C-Reactive Protein; BMI, Body Mass Index; FASN, Fatty acid synthetase; LPL, Lipoprotein lipase; FGF21, Fibroblast growth 
factor 21. 
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Table I-3 Effect of ellagic acid (EA)-containing diet from different sources intake on 
improvement of lipid profiles in small animals 
1
 
 
 
1
 Analysis was performed using meta-analysis calculator at 
http://www.healthstrategy.com/meta/meta.pl 
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Mechanisms involved in anti-obesity effects of EA 
Oxidative stress and inflammation 
Obesity is defined as chronic low-grade inflammation and increased oxidative 
stress [51]. In obese state, the inflamed adipose tissue is directly associated activation of 
inflammatory signaling with abnormal production of pro-inflammatory adipokine [52]. 
The pro-inflammatory signaling pathways are closely related to oxidative stress via 
reactive oxygen species (ROS) including free radicals [53]. It has been reported that EA 
reduces tumor necrosis factors TNF, interleukin-6 (IL-6) and chemokine C-C motif 
ligand-2 (CCL-2) secretion in lipopolysaccharides (LPS) stimulated macrophages and 
adipocytes, indicating that EA may directly reduce adipose inflammation in vitro [54]. 
Ahad et al. [50] demonstrated that EA inhibits NF-kB inhibitor, the major transcription 
factor for proinflammatory responses, for ameliorating dyslipidemia and diabetic 
nephropathy in rats. The increasing dose of EA administration (20, 40, 80, 100 mg/kg 
BW, 14 days) significantly inhibits NF-Κb-p65, transforming growth factor β (TGF-β) 
and fibronectin and proinflammatory cytokine release with the improvement of insulin 
resistance. Moreover, a recent study showed that EA (0.1 % in diet) [55] or EA-
containing pomegranate fruits extract (30 mg/kg BW) [40] improve hepatic steatosis and 
dyslipidemia by reduction of resistin [47], which is closely associated with obesity and 
chronic inflammation. Reduction of resistin release was confirmed in 3T3-L1 cells with 
20-70 M of EA treatment [40]. The direct anti-inflammatory effects of EA in white 
adipose tissue (e.g. alternative M2 macrophage polarization, changes in innate or 
adaptive immune responses) have not identified. Despite EA shows no evidence in 
accumulating in adipose tissue, our recent study clearly demonstrated that EA decreases 
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proinflammatory cytokine secretion in adipose tissue extract as well as decreases 
macrophage infiltration against high fat high sugar diet (under review).  
In addition to the attenuation of inflammation, EA supplementation is seemingly 
inhibit oxidative stress. High cholesterol/fat diet with EA supplementation (1% w/w diet) 
improved lipid profiles and decreased lipid peroxidation by reducing malondialdehyde 
(MDA) production, caspase-8, caspase-9, Fas ligand levels in aortic arches [56]. 
Consistently, EA supplementation for 14 weeks was able to protect oxidative stress-
induced endothelial dysfunction and atherosclerosis through Nrf2 activation in HF diet-
fed ApoE KO mice [57]. Intriguingly, EA supplementation (2 or 5 % of EA in diet) 
reversed STZ induced type 1 diabetic symptoms decreasing protein glycation levels and 
inflammatory action in male Balb/Ca mice [58]. These data clearly indicated that the anti-
inflammatory and anti-oxidative characteristics are sufficient to attenuate or ameliorate 
metabolic dysfunction due to obesity.  
 
Epigenetic regulation  
Accumulating evidence suggests that HF diet in early life can influence obesity 
phenotype via mechanisms associated with epigenetic modification [59]. Conversely, 
epidemiological studies show that fruits and vegetable consumption shows a reciprocal 
correlation with the incidence of obesity [12]. In respond to this new research initiatives, 
study to determine whether dietary components of fruits and vegetables participate in the 
epigenetic regulation of obesity are gradually increasing. Boque et al. reported that apple 
polyphenol consumption increases DNA methylation by attenuating adipocyte 
hypertrophy in a diet-induced obese rat model [60]. Moreover, Okla et al. also showed 
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that HF diet with MGP supplementation upregulates HDAC9 expression, which is known 
as a negative regulator of adipogenesis [34]. These data implied that dietary polyphenols 
may affect chromatin remodeling to regulate obesity outcome. Interestingly, Kang et al. 
found that EA is the responsible polyphenolic compound in MGP to increase HDAC9 
expressions, and further identified that EA inhibits histone methyltransferase (CARM1), 
an enzyme necessary for adipogenesis, during the differentiation of hASCs [35]. Even 
though there is no direct evidence that EA metabolites alter epigenetic enzymes to 
regulate obesity-associated adipose expansion, UroC was reported to reduce TNF-
induced inflammation through inhibition of histone acetyltransferase (HAT) activity in 
the monocyte cell [61]. It implies the possibility that EA metabolites may resemble the 
action of EA to modulate chromatin remodeling during adipogenesis. Not only EA, but 
also several dietary phytochemicals including curcumin [62], genistein [63], and 
isoflavone [64] are reported to improve obesity-associated metabolic index (dyslipidemia, 
hyperglycemia, and hyperinsulinemia) by altering DNA methylation and/or histone 
acetylation. An increasing number of studies are revealing that FV consumption in 
pregnancy may result in metabolic benefits to the offspring [63]. It is unknown whether 
polyphenolic constituents found in FV (including EA) may positively affect chromatin 
reprogramming of fetus, which may exert lifelong metabolic benefits against obesity and 
its associated metabolic dysfunction. Further studies in this aspect would be important to 
provide novel insights into prevention for childhood obesity as well as for adults.   
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Potential role of gut microbiota 
The gut microbial community has been proposed as a crucial environmental factor 
to control obesity by altering host’s energy homeostasis [65, 66]. The colonic microbiota 
is also responsible for the extensive breakdown of the polyphenolic structures into a 
series of phenolic metabolites that may responsible for the human health effects. Thus, 
recently, many researchers have investigated to establish the relationship between 
polyphenols supplementation and changes in the microbiome. Neyrinck et al. reported 
that mice fed with HF diet with pomegranate peel extract reduces inflammation and 
hypercholesterolemia by promoting the growth of Bifidobacterium spp. in the ceca [42]. 
Anhê et al. also described that a consumption of polyphenol-rich cranberry extract 
protects from HFHS diet-induced obesity, insulin resistance through modulation of 
microbiota ecology (Akkermansia spp. Population) of mice [67]. These data suggested 
the potential implication of the gut microbiota by dietary polyphenols. There is growing 
evidence EA or EA-enriched food consumption may attenuate obesity and its metabolic 
complications through altering gut microflora-associated metabolism, or different Uro 
production by gut microbes. Tomas-Barberan et al. suggested that different Uro is 
produced in response to host's metabolic health and that each Uro may potentiate or 
nullify the health benefits of EA [68]. In other words, metabolically healthy subjects may 
possess microbiota that are able to generate mainly active Uro such as UroA (i.e. subjects 
belonging to the so-called ‘metabotype A’ [68]). In contrast, metabolically unhealthy 
humans may have bacterial communities producing UroA but also other less active 
urolithins such as iso-UroA and UroB (i.e., subjects with ‘metabotype B’ [68]). García-
Villalba et al. reported that there were compositional differences in the gut microbiome 
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between human subjects who produce UroA (effective Uro) and who produce iso-UroA 
and B (less active Uro) [21]. Also, subjects who have a higher risk of chronic illness 
produce iso-UroA and UroB [68], the two inactive EA metabolites in our experimental 
setting (Fig. 2-4). Recently, Gordonibacter urolithinfaciens sp. nov. has been identified 
as a novel bacterial species responsible for converting EA into UroM5 and UroC [69]. 
This bacterium belongs to the family Coriobacteriaceae a family that is associated with 
benefits in obesity [70]. Since the bacterial phylum that specifically transform EA or its 
intermediate metabolites into UroA vs. iso-UroA/UroB have not yet been identified, it 
could be of interest for future studies.   
 
Implications and Conclusion 
The excessive expansion of white adipose tissue during obesity triggers complex 
and multifactorial conditions of chronic inflammation and oxidative stress. In this review, 
we summarized that EA plays a critical role in attenuating the prevalence of obesity by 
decreasing both hyperplastic and hypertrophic adipocyte expansion in vivo and in vitro.  
In terms of mode of action by which EA attenuates obesity-mediated metabolic 
dysfunction, the anti-oxidative and anti-inflammatory characteristics of EA have been 
presented. In addition, we have been addressed the emerging role of EA in modifying 
histone remodeling by altering methylation and/or acetylation levels of histone and 
potential role of Uro in regulating gut microbial community. A better explanation to fill 
the gap between ‘low bioavailability’ and ‘evident benefits of EA in improving plasma 
lipid profiles’ should be identified in future studies.  
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Hitherto, human studies are concentrated on determining the bioavailability of EA 
by using various EA-containing whole foods such as pomegranate extracts, or 
intervention studies for cancer treatment. The investiagtion of metabolic benefits of EA 
in humans against obesity and its metabolic complication, should be the next-step 
challenge to validate the ‘proof of concept’ that we learned from obesity-prone 
experimental animals with EA supplementation. In conclusion, recommanding an 
inclusion of EA-containg fruits and nuts in our daily diets potentially could be a simple 
strategy to lessen adiposity or improve obesity-mediated metabolic complication even 
without weight loss.  
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HYPOTHESIS AND SPECIFIC AIMS 
The central hypothesis for this dissertation research is that dietary ellagic acid 
(EA) attenuates obesity and obesity-mediated metabolic complications.  To test this 
hypothesis, the following four specific aims were pursued using primary cultures of 
newly differentiated / mature human adipocytes as an in vitro model, and obesity-prone 
C57BL/6 mice as an in vivo model (Figure I-5).  
 
Aim 1. Define that EA exerts the lipid-lowering effects both in adipose tissue and 
liver via distinct mechanisms (Chapter I).  
Aim 2. Determine the mechanisms underlying EA’s effects on modulating new fat 
cell formation by CARM1-mediated epigenetic regulation (Chapter II).  
Aim 3. Ascertain the effects of EA on the obesity and obesity mediated oxidative 
stress/inflammation in a mice model (Chapter III). 
Aim 4. Evaluate the effects of gut microbiota-driven EA metabolites, Uro, on 
regulating TG accumulation using primary-cultured human adipocytes (Chapter IV). 
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Figure I-5 The central hypothesis and aims of this dissertation research. 
The central hypothesis of this research project is that dietary ellagic acid (EA) 
attenuates obesity and obesity-mediated metabolic complications. To test the hypothesis, 
in Aim #1, I focused on lipid-lowering effects of EA both in adipose tissue and liver via 
distinct mechanisms. In Aim #2, I focused on anti-adipogenic effects of EA via CARM1-
mediated epigenetic regulation. In Aim #3, I ascertained the effects of EA on the 
prevention of obesity and its metabolic complications in a mouse model. Lastly, in Aim 
#4, I focused on whether EA-metabolites, Uro, resemble the health beneficial effects of 
EA in human adipocytes. 
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Abstract 
Previously, we have reported that supplementation of muscadine grape phytochemical 
(MGP) decreased lipid accumulation against the high fat (HF)-diet. The aim of this study 
was to identify responsible polyphenolic constituents and to elucidate the underlying 
mechanisms. In mice, MGP supplementation significantly reduced visceral fat mass as 
well as adipocyte size. To determine whether MGP affects adipogenesis or hypertrophic 
lipid accumulation, we used human adipogenic stem cell (hASCs) model. Among the 
MGP, ellagic acid (10 mol/L) was identified as a potent negative regulator in repressing 
adipogenesis of hASCs. In addition, ellagic acid substantially decreased the conversion of 
[
3
H]-acetyl CoA into fatty acid, suggesting that ellagic acid inhibits de novo synthesis of 
fatty acid in mature adipocytes. Similarly, MGP supplementation significantly decreased 
hepatic TG contents in liver. The TG-lowering effects of ellagic acid was confirmed in 
human hepatoma Huh7 cells. Ellagic acid reduced 
3
H-oleic acid esterification into [
3
H]-
TG as well as de novo the synthesis of fatty acid from 
3
H-acetyl CoA in Huh7 cells. 
Intriguingly, ellagic acid also increased oxygen consumption rate and -oxidation related 
gene expression. Taken together, ellagic acid attenuates new fat cell formation and fatty 
acid biosynthesis in adipose tissue, while it reduces the synthesis of triglyceride and fatty 
acid and increases fatty acid oxidation in liver. These results suggest that ellagic acid 
exerts unique lipid-lowering effects both in adipose tissue and liver via distinct 
mechanisms. 
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1. Introduction 
Liver and adipose tissue are two major organs regulating the whole body lipid 
metabolism. Excessive lipid accumulation in fat and liver is a hallmark of obesity and 
metabolic syndrome. Obesity is characterized by abnormal expansion of white adipose 
tissue either by increasing number of adipocytes from mesenchymal progenitor cells 
(adipocyte hyperplasia) or by simply increasing its size (hypertrophy). The number of 
adipocytes is tightly controlled after puberty [1]. However, abnormal increase of 
adipocyte number is evident in childhood obesity and also frequently associated with 
extreme obesity in adults [2]. In contrast, enlargement of the adipocytes is the most 
common mechanism to accommodate surplus energy in the form of triglyceride in adults. 
It is well established that the adipocyte hypertrophy is concurred with adipose 
inflammation [3, 4]. Enlarged and inflamed adipocytes are key contributors to the 
pathogenesis of obesity by impairing endocrine function of adipocytes [5]. Although it is 
controversial that hyperplastic expansion of subcutaneous fat could be a defense 
mechanism to attenuate lipotoxicity, adipocyte hyperplasia also results in metabolically 
unfavorable ectopic adipogenesis and increases the risk for cardiovascular diseases 
(reviewed in [6]), suggesting that both hyperplastic and hypertrophic expansion of 
adipocytes are associated with adipocyte remodeling during the pathogenesis of 
metabolic syndrome [7].  
The development of hepatic steatosis is intimately associated with the 
pathological conditions of adipocytes. Redistribution of fat in lipodystrophic conditions 
such as diabetes or uncontrolled lipolysis from the inflamed adipocytes increases the 
influx of FFA into the portal vein leading to hepatic steatosis [8]. Reversely, fatty liver is 
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a significant risk factor for hyperlipidemia, insulin resistance, and diabetes [9]. 
Supporting this notion, it has been reported that 76% of those with nonalcoholic fatty 
liver disease (NAFLD) are obese [10].  
Attenuation of obesity by limiting adipocyte’s capacity to expand (inhibition of 
either hypertrophic or hyperplastic expansion) is a general target of dietary 
supplementation, which may lead to detrimental consequences if the surplus FFA are re-
directed into liver. Some food-borne dietary compounds that were claimed to be effective 
in attenuating adiposity (e.g., trans-10, cis-12 conjugated linoleic acid)  had to be 
reevaluated its value due to an adverse side effect on hepatic steatosis [11, 12]. Recently, 
our group has reported that supplementation of muscadine grape phytochemicals (MGP) 
decreased visceral fat mass [13]. In addition, MGP supplementation was effective in 
reducing systemic and retinal inflammation, and glucose intolerance [13, 14].  However, 
the crosstalk of lipids between liver and adipose tissue by MGP has not been fully 
investigated yet. The aim of this study was 1) to identify the polyphenolic compounds 
posing the lipid-lowering effects of MGP and 2) to investigate the metabolic modification 
by MGP in adipocytes as well as in hepatocytes. Here we identified that ellagic acid 
inhibits adipogenesis and decreases lipid accumulation both in mature human adipocytes 
and hepatocytes via distinct mechanisms. Our results also suggest that ellagic acid may 
constitute consumer-friendly dietary strategy that may effective in reducing lipid 
accumulation both in adipose and liver.    
 
2. Materials and Methods 
2.1 Chemicals  
33 
 
 
 
Fetal bovine serum (FBS) was purchased from Cellgro. Rosiglitazone (BRL49653) 
was purchased from Cayman Chemical. All other chemicals and reagents were purchased 
from Sigma Chemical Co., unless otherwise stated.  
2.2. Animals 
 The adipose tissue and liver samples were collected from our previous study [13]. 
Tissue was fixed in 10% buffered formaldehyde for paraffin embedding and hematoxylin 
and eosin (H&E) staining. All protocols and procedures were approved by the 
Institutional Animal Care and Use Committee (IACUC) at the University of Florida.  
2.3. Cell culture 
 For isolation of human adipogenic stem cells (hASCs), abdominal adipose tissue 
was obtained from females with a body mass index (BMI) of ~30 during liposuction or 
abdominal plastic surgeries. Isolation of hASCs and differentiation of adipocytes was 
conducted as we described previously [15]. All protocols and procedures were approved 
by the Institutional Review Board (#693-2011) at the University of Florida and the 
University of Nebraska. Huh7 cells were a kind gift from Dr. Kim (the University of 
Florida). Huh7 cells were maintained in Dulbecco’s modification of Eagle’s medium 
(DMEM) containing 1% L-glutamine, 10% fetal bovine serum, 100 units/ml penicillin, 
100  g/ml streptomycin in 5% CO2 at 37°C. The medium was changed every 3 days.  
2.4. Adipocyte size measurement  
H&E stained-sections of epididymal adipose tissue were used for size 
determination by following the published protocol by Chen et al. [16]. Briefly, adipocyte 
size was examined by analyzing digital images of H&E stained paraffin sections (n=300 
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cells /mouse, total=1,500-2,000 adipocytes from 7-9 mice/diet group) by using Image J 
software.  
1.5. Lipid accumulation  
The colorimetric triglyceride quantification kit (BioVision, K622‐100) was used 
to quantify the hepatic TG contents according to the manufacturer's protocol. To measure 
the lipid accumulation in human adipocytes and Huh7 cells, cells were fixed with 
isopropanol and stained with oil-red O. For determination of relative TG contents, bright 
field images were taken by eVOS XL microscope (AMG), or ORO dye was extracted for 
quantification (OD500 nm).  
1.6. Preparation of MGP and sub-fractionation 
Preparation of MGP has been described by Gourineni et al. [13]. The 
subfractionation of MGP into non-anthocyanin (NAcy) and anthocyanin (Acy) was 
completed as described previously [17]. To examine the effects of different 
phytochemicals on hASCs differentiation, ellagic acid (EA), quercetin (Quer), myricetin 
(My), and kaempferol (KMP) (Sigma) stocks were prepared in dimethyl sulfoxide 
(DMSO); aliquots of each stock were kept at -20 °C and freshly diluted at the time of 
addition to hASCs. The presence of intracellular lipid accumulation was visualized by oil 
red-O (ORO) staining.   
 2.7 [
3
H]-oleic acid and [
3
H]-acetyl CoA incorporation into FFA and TG 
To measure fatty acid esterification rate into triglycerides, we followed the 
previously published methods by Chung et al. [18] in cultures of mature adipocytes or 
human hepatoma Huh7 cells were used. Briefly, cells incubated with serum-free low 
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glucose (1,000 mg/L d-glucose) overnight before experiment. 
3
H-oleic acid (Perkin 
Elmer, final concentration of 0.5 Ci/mL) was complexed with fatty acid-free BSA, then 
added to cells for 3 hr (a time course study indicated a linear incorporation into cellular 
TG fraction over a 6 hr period; data not shown). After 3 hr incubation with 
3
H-oleic acid, 
medium containing unincorporated isotope was removed by washing PBS. The cellular 
lipids were extracted by Bligh and Dyer method. Then thin layer chromatography was 
performed to fractionate FFA and TG, and the [
3
H] radioactivity was measured by liquid 
scintillation counting (Beckman LS 6000; Beckman Instruments, Palo Alto, CA). 
Radioactivity was normalized by protein concentration quantified by bicinchoninic acid 
(BCA) colorimetric assay (Pierce, Rockford, IL). Similarly, for the measurement of de 
novo synthesis of fatty acid, [
3
H]-acetyl CoA (Perkin Elmer, final concentration of 0.5 
Ci/mL) were added to cells for 3 hr and unincorporated isotope was removed by 
washing PBS three times. 
2.8. [
3
H] 2-deoxy-glucose uptake 
To determine the basal, and insulin-stimulated glucose uptake, cultures of mature 
human adipocytes were incubated with or without 10mol/L of EA for 3 days. The day 
before the experiment, cultures were incubated with 1ml serum free basal medium 
containing 1,000 mg/L d-glucose and 20 pmol/L human insulin (Thermo scientific, 
SH30021.01) in the presence of vehicle or treatment. After 24hrs serum starvation, 
culture media was removed and replaced with 1 ml of HBSS buffer containing 100 
nmol/L human insulin for 10 min then add [
3
H]-2DOG (Perkin Elmer, final concentration 
was 0.5 Ci/mL) and incubated at 37°C for 90 min. Glucose uptake was terminated by 
adding 1 ml of stop buffer (ice-cold Krebs-Ringers bicarbonate (KRBC) buffer 
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supplemented with 25mmol/L d-glucose. After washing cells with KRBC buffer three 
times to reduce background radioactivity, cells were lysed in 0.1% SDS. The total 
cellular lysates were subjected to determine glucose uptake by liquid scintillation 
counting [19] . 
2.10. Oxygen consumption rate (OCR)  
Huh7 cells were seeded into 96-well clear bottom black polystyrene sterile plate 
(Corning). Oxygen consumption rate (OCR) was determined by using the assay kit 
MitoXpress
®
 (Cayman Chemical, 600800) according to the manufacturer’s protocol. 
Briefly, an increase of phosphoresce signal from the oxygen-sensitive probe was 
measured over 5 hr with 3 minutes interval using Synergy H1 multi-mode microplate 
reader (BioTek).   
2.11. qPCR 
Gene-specific primers for qPCR were obtained from Integrated DNA 
Technologies (Chicago, IL). Total mRNA of hASCs was isolated using Trizol reagent 
(Invitrogen). To remove genomic DNA contamination, mRNA was treated with DNase 
(Mediatech); 2 μg of mRNA was converted into cDNA in a total volume of 20 µL 
(iScript cDNA synthesis kit, Bio-Rad). Gene expression was determined by real-time 
qPCR (CFX96, Bio-Rad), and relative gene expression was normalized by 36b4 (primer 
sequences will be available upon request).  
2.12. Western blot analysis 
To prepare tissue lysates, 0.1 g of snap-frozen tissue was homogenized in ice-cold 
RIPA buffer (Thermo Scientific) with protease inhibitors (Sigma) and phosphatase 
inhibitors (2 mmol/L Na3VO4, 20 mmol/L β-glycerophosphate and 10 mmol/L NaF). 
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Lysate of adipose tissue was incubated in ice for 10 minutes to remove the solidified fat 
cake. To prepare total cell lysates, monolayers of differentiated cultures of human 
adipocytes were harvested with RIPA buffer. Proteins were fractionated onto 4-15% pre-
casted SDS-PAGE (Biorad), transferred to PVDF membranes with a semi-dry transfer 
unit (Hoefer TE77X) and incubated with the relevant antibodies. Chemiluminescence 
from ECL (Western Lightning) solution was detected with FluorChem E (Cell 
Biosciences) imaging system. Polyclonal or monoclonal antibodies targeting to FAS 
(3180), β-actin (4967), and H3K9Ac (AcH3, 9649) were purchased from Cell Signaling 
Technology. Antibodies targeting HDAC9 (ab 59718) and histone H3 (ab1791) were 
purchased from Abcam. The mouse monoclonal antibodies for PPAR (sc-7273), FABP 
(aP2, sc-271529) were purchased from Santa Cruz Biotechnology.  
2.13. Statistical analysis 
Results are presented as the mean ± SEM. The data were statistically analyzed 
using Student’s t-test or one-way ANOVA with Tukey’s multiple comparison tests. For 
the analysis of adipocyte size, Gaussian curve fitting and linear regression were 
performed. To calculate oxygen consumption rate, linear regression (95% confidence, 
p<0.05 significant) was conducted. All analyses were performed with GraphPad Prism 6 
(Version 6.02).  
 
3. Results 
3.1 MGP supplementation attenuated adipocyte size in C57BL/6 mice  
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Previously, we reported that the supplementation of MGP (Vitis rotundifolia) 
significantly reduced HF-diet induced epididymal fat mass [13]. However, mechanistic 
details by which MGP supplementation reduced adiposity is unknown. To determine 
whether MGP decreases adipocyte hypertrophy, we first examined epididymal adipocyte 
size by analyzing digital images of H&E stained paraffin sections. Consistent with the 
reduced epididymal fat mass (Fig. 1A), adipocyte size was significantly reduced with 
MGP supplementation compared to HF alone (Fig. 1B, 86.8 ± 2.8, 100.6 ± 3.3 and 86.5 ± 
1.4 µm for LF, HF, and HF+MGP, respectively). Histograms of adipocyte size 
distribution also demonstrated a clear shift toward smaller sizes for the HF+MGF group, 
which is comparable to LF control (Fig. 1C, D).  
 
3.2. EA in MGP is a potent negative regulator of adipogenesis 
To gain insights into whether MGP supplementation also decreases hyperplastic 
expansion of adipocytes (adipogenesis) as well as hypertrophic expansion of adipocytes 
(Fig 1), we examined protein expression that are known to influence adipogenesis. As we 
expected, PPAR expression levels were higher in the HF group in comparison to LF or 
HF+MGP group. Interestingly, HDAC9 expression, a negative regulator of adipogenesis 
[20], was reduced in the HF group compared to LF or HF+MGP. Conversely, histone 
lysine 9 acetylation (H3K9Ac) levels, a positive epigenetic marks for adipocyte 
differentiation, were markedly increased in the HF group compared to LF or HF+MGP 
(Fig. 2A), providing a hint that adipocyte differentiation might be reduced by MGP 
supplementation. To pursue this possibility, we conducted in vitro studies using adipose-
derived human stem cells (hASCs). First, we fractionated MGP into Acy and NAcy 
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fractions. The effect of each fraction on adipocyte development was examined. The 
anthocyanin fraction had significant but minor impact on adipogenesis. In contrast, the 
NAcy fraction dramatically suppressed lipid accumulation in a dose-dependent manner as 
assessed by oil red O (ORO) staining (Fig. 2B,C). Consistent with reduced TG 
accumulation, the NAcy fraction of MGP dramatically suppressed adipogenic gene 
expression including PPAR and adipocyte protein 2 (aP2) (Fig 2D). Next, we performed 
HPLC analysis and found that the NAcy fraction composed of four major polyphenols, 
EA, My, Quer and KMP (Fig. 3A). When hASCs were exposed to 10 µM of these 
individual pure polyphenols, EA almost exclusively repressed the adipogenesis compared 
to the other polyphenols. In in vitro model of human adipocytes, EA decreased: 1) TG 
accumulation as assessed by ORO-staining (Fig. 3B); 2) adipogenic gene expression by 
qPCR including PPAR, CCAAT/enhancer binding protein alpha (C/EBP), aP2, and 
fatty acid synthase (FAS) (Fig. 3C); and 3) adipogenic protein expression including 
PPAR, aP2, and FAS (Fig. 3D).  
 
3.3. EA attenuated lipid accumulation in mature adipocytes 
Next, we asked whether EA is the key polyphenolic component that antagonizing 
the adipocyte hypertrophy as we have observed in Fig.1, as well as suppressing 
adipogenesis. To answer this question, EA was treated to the fully-differentiated cultures 
of human adipocytes (d7). EA incubation was last for 3 or 7 days depends on 
experimental design in Fig 4A. Addition of 10µM EA for 7 days caused a significant 
reduction of triglyceride accumulation by oil red O staining (Fig. 4B). To test whether the 
decrease of triglyceride accumulation is due to an alteration of lipogenic pathways, [
3
H]-
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acetyl CoA and [
3
H]-oleic acid was added to the adipocytes and examined its conversion 
into triglyceride. The conversion of [
3
H]-acetyl CoA to radiolabeled FFA (Fig. 4C) and 
TG (Fig. 4D) was almost completely blunted by 3 days of EA treatment. However, 
exposure of EA exert no significant impact on conversion of 
3
H-oleic acid into [
3
H]-TG 
at 3days (Fig. 4E). In addition, the basal- and insulin-stimulated [
3
H]-2-deoxyglucose 
uptake was not affected by EA treatment (Fig. 4F). The extended treatment of EA for 7 
days decreased adipocyte specific mRNA expression including PPAR, C/EBP, and 
fatty acid synthase (FAS) compared to vehicle control (no changes in adipogenic genes in 
EA treatment for 3 days, data not shown). There were no significant changes in fatty acid 
oxidation-related gene expression (PPAR and CPT1), but lipolysis related genes 
expression (i.e., hormone sensitive lipase (HSL) and adipocyte triglyceride lipase 
(ATGL)) was substantially lower in EA treated adipocytes (Fig. 4G). Taken together, 
these data implicates that the inhibition of de novo synthesis of fatty acid is accompanied 
by transcriptional regulation of lipogenic gene expression in EA-treated human 
adipocytes.  
3.4. MGP decreased hepatic lipid accumulation in C57BL/6 mice  
Attenuation of adipogenesis could cause hepatic steatosis if the liver mishandles 
fatty acid (FA) influx from adipose tissue [21]. To determine the effects of MGP on 
hepatic lipid metabolism, we also measured hepatic TG contents. H&E staining showed a 
reduction of hepatic lipid accumulation in HF+MGP group compared to HF only group, 
which was confirmed by ~50 % reduction of hepatic TG content in MGP-fed group 
compared to HF group (Fig. 5A,B). Interestingly, fatty acid oxidation-related genes 
including PPAR, FGF21, ACOX1 and CPT1 were significantly higher in the MGP 
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group (Fig. 5C), suggesting that MGP decreased hepatic TG accumulation, at least in part, 
by augmenting hepatic fatty acid oxidation as well as attenuating adipocyte expansion.  
3.5. EA attenuated lipid accumulation in Huh7 cells 
 To determine whether EA is the primary polyphenolic compound in reducing 
hepatic triglyceride accumulation, we further examined effects of EA on fatty acid 
esterification, de novo synthesis, and FA oxidation in human hepatocarcinoma Huh7 cells. 
Pretreatment with EA for 24 hr significantly attenuated lipid accumulation in a dose-
dependent manner in Huh7 cells (Fig. 6A). In parallel to MGP-fed mice this, mRNA 
expression of fatty acid β-oxidation relative genes such as PPAR and carnitine 
palmitoyltransferase 1 (CPT1) was up-regulated, but not ACOX1, in EA treated samples. 
In contrast, genes involved in lipogenesis, i.e., FAS and diacylglycerol acyltransferase 2 
(DGAT2), were significantly reduced by EA treatment without affecting stearoyl-CoA 
desaturase 1(SCD1) gene expression (Fig. 6B). Accordingly, the oxygen consumption 
rate, measured by oxygen-sensitive phosphoresce probe, was higher in Huh7 cells treated 
with EA than vehicle control (Fig. 6C) demonstrating an up-regulation of fatty acid 
oxidation by ellagic acid in hepatocytes. Interestingly, the uptake of [
3
H]-oleic acid (OA) 
into the cells was similar between groups (Fig. 6D), while incorporation of [
3
H]-oleic into 
TG was significantly lower in Huh7 cells treated with EA (Fig. 6E). Similar to adipocytes, 
incorporation of 
3
H-acetyl CoA into FFA and TG was markedly decreased with EA 
treatment (Fig. 6F,G). Collectively, our data clearly showed that MGP and its active 
polyphenolic constituent ellagic acid decrease hepatic lipid accumulation by targeting 
multiple mechanisms including FFA synthesis, TG esterification, and FFA oxidation.    
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4. Discussion 
Obesity and hepatic steatosis are the two manifest phenotypes of metabolic 
syndrome and are inextricably linked together. The simultaneous reduction of lipid 
accumulation both in adipose tissue and liver would be the ultimate goal for the dietary 
intervention strategies. The present study was designed to determine the TG-lowering 
effect of MGP supplementation on adipose and liver, and to identify the metabolic 
alterations by ellagic acid by using the human model of adipocyte and hepatocytes in 
parallel. We demonstrated that the supplementation of MGP attenuated hypertrophic 
obesity (Fig. 1) and hepatic steatosis (Fig. 5) in HF-fed mice. Ellagic acid has been 
identified as the active polyphenolic compound that suppressed the hyperplastic 
expansion of adipocytes (Fig. 2, 3). Besides, ellagic acid exerted the distinctive lipid-
lowering properties by decreasing biosynthesis of fatty acid in both adipocytes and 
hepatocytes but by augmenting fatty acid oxidation only in hepatocytes (Fig. 4, 6). Our 
data provide the first evidence that ellagic acid plays separate roles in manipulating 
excess lipid in adipocytes versus hepatocytes, resulting in a concerted attenuation of 
obesity and hepatic steatosis. Collectively, our results suggest that ellagic acid-containing 
foods may constitute a novel and effective dietary strategy to prevent and/or treat obesity 
and metabolic syndrome. 
Muscadine grape (V. rotundifolia) contains an array of health-promoting bioactive 
phytochemicals [22-24]. Our previous study has provided the implication that unique 
lipid-lowering property of MGP may attribute to the high content of ellagic acid [13]. In 
the present study, we proved that ellagic acid exhibits broad action spectrum by targeting 
to multiple mechanisms, i.e., adipocyte differentiation, de novo synthesis of fatty acid, 
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FA esterification, and FA oxidation, probably through different mechanisms in liver and 
adipose tissue. Numerous reports implicated that ellagic acid-containing fruits, vegetables, 
and nuts are effective dietary sources to attenuate obesity. However, direct evidence of 
the underlying mechanism of how ellagic acid displays an anti-obesity effect, has not 
been addressed yet. To better understand the relationship between the ellagic acid intake 
and adiposity, we have reviewed and combined the results from published, peer-reviewed 
literature, mainly in rodents [13, 25-31] (Supplement Table 1). Despite the variations 
related to the differences in sources and contents of ellagic acid,  daily intake of ellagic 
acid in the range of 5-88 mg/kg BW was strongly correlated with >25% decrease of fat 
mass (with minor impact on lean body mass), and improvement of glucose metabolism. 
The conclusion deduced from these summary (Supplement Table 1) correlates with our 
present data that EA-enriched MGP is associated with a reduction of fat mass, adipocyte 
hypertrophy, and hepatic lipid accumulation. Interestingly, the muscadine wine extract 
that has almost identical phytochemical composition except for markedly reduced ellagic 
acid content due to filtration [32], was lack of lipid-lowering effects. It provides us with 
additional rationale to draw the conclusion that ellagic acid is a key ingredient of MGP to 
reduce fat mass.  
It has been well documented that ellagic acid possesses anti-proliferative and anti-
inflammatory characteristics in various cancerous cell lines [25, 33]. Also, ellagic acid 
has shown to be effective in reducing atherosclerotic lesions [34] and increasing 
cholesterol efflux in macrophages [35]. In this study, we add the previously 
unappreciated value of ellagic acid as a lipid-lowering dietary compound both in adipose 
and liver. The reduction of adiposity attribute to a reduction of both hyperplastic and 
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hypertrophic expansion of adipocytes. The inhibitory effects of MGP (or ellagic acid) on 
adipogenesis seem to be associated with, at least partly, epigenetic modification (Fig. 2, 
3). Recently, ellagic acid was identified as a negative regulator of histone 3 arginine 17 
methylation (H3R17me) by inhibiting CARM1 (coactivator-associated arginine 
methyltransferase 1) in cancerous cells [36]. Given to the fact that CARM1 activity is 
required for adipogenesis [37], we investigated the epigenetic regulation of adipogenesis 
by ellagic acid in a separate study using the same primary human adipocytes. In that 
study, we demonstrated that ellagic acid alters epigenetic marks of adipocyte 
differentiation by altering histone deacetylase (HDAC) activity, acetylation, and 
methylation levels. It may align well with the study by Wang et al. showing that ellagic 
acid inhibits differentiation of 3T3L1 preadipocyte into adipocytes by inhibiting mitotic 
clonal expansion [38], although primary adipogenic progenitor cells do not enter mitotic 
clonal expansion and the involvement of CARM1 need to be verified in 3T3L1 cells.  
The attenuation of the hypertrophic expansion (increase in size by excessive TG 
accumulation) was clearly detectable both in epididymal fat of MGP-fed mice (Fig. 1) as 
well as in the ellagic acid-treated mature adipocyte cultures (Fig. 4). A reduction of FA 
biosynthesis in mature adipocytes (Fig. 4C) was an earlier event than transcriptional 
down-regulation of adipogenic gene expression (Fig. 4G). Conversely, FA esterification 
into TG, glucose uptake (both basal- and insulin-stimulated), and fatty acid oxidation 
were not altered by ellagic acid at the same window of time when fatty acid biosynthesis 
is markedly reduced by ellagic acid. It is unlikely that the inhibition of fatty acid 
synthesis is due to diminished CARM1 activity, as we do not examine the differences in 
H3R17me levels in mature adipocytes before and after ellagic acid treatment (data not 
45 
 
 
 
shown). Based on our results, there is a likelihood that ellagic acid may directly affect 
fatty acid synthase (FAS). We are currently under investigation whether ellagic acid 
alters global lipid metabolism using the different mutant strains of yeast (Saccharomyces 
cerevisiae) carrying deletion of critical genes related to lipid metabolism.   
The impact of MGP and ellagic acids on lipid metabolism in the liver was more 
phenomenal than in adipose tissue. MGP supplementation decreased hepatic TG content 
by ~50% compared to HF alone, probably through the augmented fatty acid oxidation 
(Fig. 5). In agreement with our findings, Yoshimura et al. reported that supplementation 
of 0.1% of ellagic acid for 68 days was effective in decreasing hepatic steatosis by 
increasing mRNA expression of PPAR and CPT1 genes in  KK-Ay mice, a model of 
obesity type 2 diabetes [39]. Consistently, we were able to reproduce that ellagic acid 
lowered TG accumulation (Fig. 6A), increased of fatty acid oxidation-related gene 
expression (Fig. 6B) and, more importantly, oxygen consumption rate (Fig. 6C) in human 
hepatoma cells. Moreover, despite that it was less evident in MGP-fed mice, ellagic acid 
decreased FA uptake, de novo synthesis, and its esterification into TG (Fig6. D-G). These 
TG-lowering effects are also supported by ellagic acid supplementation in rats [31], and 
our pilot study with pure ellagic-fed mice supplementation (unpublished data). The exact 
mechanistic nature by which ellagic acid targets to multiple metabolic pathways in liver 
is uncertain. Some potential mechanism that ellagic acid represses de novo synthesis of 
FA could be found. Sarikaya et al. showed that  ellagic acid is an inhibitor of carbonyl 
anhydrolase (CA) activity [40], and a reduction of CA activity has been associated with 
lowering  hepatic de novo lipid synthesis in primary rat hepatocytes [41]. We are 
currently investigating the two possibilities that 1) ellagic acid may change epigenetic 
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marks such as H3R17me2 by CARM1 [36],  leading to transcriptional inhibition of 
lipogenic gene expression in hepatocytes, and 2) ellagic acid directly inhibits lipogenic 
enzyme activities including fatty acid synthase (FAS) and acetyl CoA carboxylase 
activity (ACC). 
Free ellagic acid can be found in plasma up to ~1mol/L concentration after oral 
administration [42], but it rapidly metabolizes into urolithins by gut microbes [43]. Our 
current study design has the obvious limitations to translate into humans, as we used the 
10 mol/L ellagic acid in 0.1 % DMSO, and metabolite information was not taken into 
consideration in cellular studies. Intriguingly, treatment of physiologically achievable 
concentration of ellagic acid (<1 mol/L), took the longer period of time to detect the 
measurable reduction of TG levels in hepatocytes and adipocytes (unpublished data), 
implicating that reduction of lipid accumulation could be attainable via chronic 
supplementation of ellagic acid-containing diet. Actually, pure ellagic acid (0.08 %) 
supplementation for 8 wks was effective in reducing fat pad size and liver weight against 
HF diet in rats [31].  Our pilot study with 0.1 % of ellagic acid supplementation for 12 
wks reduced the liver lipid contents (data not shown). We are under investigation to 
determine whether urolithin A, the major metabolite of ellagic acid, could reiterate 
multiple lipid-lowering effects of ellagic acid with greater biological potency than ellagic 
acid.    
In summary, here we identified ellagic acid as the primary polyphenolic 
component to lower triglycerides among MGP, and delineated the metabolic pathways 
that affected by ellagic acid in adipocyte and hepatocytes. There are unanswered 
questions regarding physiological levels of ellagic acid and generation of microbial 
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metabolites, but we believe, nonetheless, our works provide mechanistic insights into 
lipid-lowering effects of ellagic acid. It is the first report that separately investigated the 
lipid-lowering effects of ellagic acid in adipose and liver. More research will be 
implemented for better understanding of multiple metabolic benefits of ellagic acid-
containing foods.  
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Figure II-1 MGP supplementation attenuated fat mass and adipocyte size.   
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Figure II -2 NAcy constituents of MGP were associated with a decrease of adipocyte 
differentiation. 
A, Protein expression of PPAR, aP2, HDAC9, H3K9Ac, and H3 by western blot 
analysis from the mice fed with either low fat (LF), high fat (HF), or HF+0.4% MGP for 
15 wks. Cultures of hASCs were differentiated and incubated with either Acy or NAcy 
fractions for seven days. B, Triglyceride Lipid accumulation in 96 well culture plates was 
visualized by ORO-staining (upper). Extracted ORO-staining was quantified (OD500 nm) 
(lower). C, Bright field images with ORO-staining for cultures differentiated with 
different doses of NAcy and Acy. D, Adipogenic gene expression of PPARand aP2 by 
qPCR analysis. All values are presented as the mean ±SEM. Means not sharing a 
common superscript differ, p<0.05.    
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Figure II -3 EA suppressed adipogenesis of hASCs. 
Cultures of hASCs were induced to differentiation in the presence of either vehicle (Veh) 
or 10 μmol/L of NAcy components of EA, My, Quer, and KMP. A, HPLC chromatogram 
showing major phenolic constituents of NAcy fraction in MGP. B, Effects of individual 
polyphenols on TG accumulation measured by ORO-staining. C, Adipogenic gene 
expressions of PPAR, aP2, C/EBPand FAS by qPCR analysis. D, Adipogenic protein 
expression of PPAR, Fas, and aP2 by western blot analysis. All values are presented as 
the mean ±SEM. Means not sharing a common superscript differ, p<0.05.   
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Figure II -4 EA decreased triglyceride accumulation in mature human adipocytes. A. 
Experimental scheme. 
EA (10M) was added to the newly differentiated human adipocytes (at day 7) and 
incubated for 3-7 day. Experiments were conducted at the given time (arrows). B, Lipid 
accumulation was visualized by ORO-staining. C, Conversion of [
3
H]-acetyl coA into 
[
3
H]-fatty acid. D, Conversion of [
3
H]-acetyl CoA into [
3
H]-triglyceride. E, Conversion 
of [
3
H]-oleic acid into 
3
H-TG. F, Basal and insulin-stimulated [
3
H]-2-deoxyglucose 
uptake. G, Gene expression levels of PPAR, C/EBP, FAS, PPAR, and CPT1 by 
qPCR. In C-F, data were normalized by protein concentration. All values are presented as 
the mean ±SEM, * p< 0.05, **p<0.01, and **** P < 0.0001 by student t-tests.    
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Figure II -5 MGP supplementation decreased hepatic lipid accumulation. 
C57BL/6 mice were fed with either high fat (HF) or HF + 0.4% MGP for 15 wks. A, 
H&E staining for liver tissues. B, TG content in liver. C, mRNA levels of PPARα, 
FGF21, ACOX1 and CPT1 in liver by qPCR. All values are presented as the mean ±SEM, 
**** P < 0.0001, * P< 0.05.  
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Figure II -6 EA decreased triglyceride accumulation in human hepatoma Huh7 cells. 
Huh7 cells were preincubated overnight with or without (w/o) ellagic acid (EA). A, Lipid 
accumulation quantified by oil red O staining in Huh7 cells that received 5 or 10 mol/L 
of EA. B,  mRNA expression levels involved in FA β-oxidation and lipogenesis by qPCR. 
C, Oxygen consumption rate (OCR) in the presence or absence of EA. D, Uptake of 
3
H-
oleic acid (OA) into cells. E., Conversion of   [
3
H]-OA into [
3
H]-triglyceride (TG). F, 
Conversion of [
3
H]-acetyl CoA into [
3
H]-FFA. G, Conversion of [
3
H]-acetyl CoA into 
[
3
H]-TG.  
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Supplement Table 1. Effect of ellagic acid (EA)-containing diet on adiposity from 
different sources
1
  
 
1 
Analysis was performed using meta-analysis calculator at 
http://www.healthstrategy.com/meta/meta.pl 
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ABSTRACT 
Chromatin remodeling is a key mechanism in adipocyte differentiation. However, it is 
unknown whether dietary polyphenols are epigenetic effectors for adiposity control. 
Recently, we have identified that ellagic acid (EA), a naturally occurring polyphenol in 
numerous fruits and vegetables, represses adipogenic conversion of human adipose-
derived stem cells (hASCs). In the present study, we sought to determine whether EA 
inhibits adipogenesis by modifying chromatin remodeling in hASCs. qPCR microarray of 
chromatin modification enzymes revealed that 10 mol/L of EA significantly inhibits 
histone deacetyase (HDAC) 9 down-regulation. In addition, EA was associated with an 
up-regulation of HDAC activity and a marked reduction of histone acetylation (HAc) 
levels. However, chemical inhibition of HDAC activity or depletion of HDAC9 by 
siRNA were not sufficient to reverse the anti-adipogenic effects of EA. Intriguingly, EA 
treatment was also associated with reduced histone 3 arginine 17 methylation levels 
(H3R17me2), implying the inhibitory role of EA in coactivator-associated arginine 
methyltransferase 1 (CARM) 1 activity during adipogenesis. Boosting CARM1 activity 
by delivering cell-penetrating peptides of CARM1 (CPP-CARM1) not only recovered 
H3R17me2, but also restored adipogenesis evidenced by H3K9Ac, HDAC9 
downregulation, PPAR expression, and triglyceride accumulation. Taken together, our 
data suggest that reduced CARM1 activity by EA results in a decrease of H3R17me2 
levels, which may interrupt consecutive histone remodeling steps for adipocyte 
differentiation including histone acetylation and HDAC9 dissociation from chromatin. 
Our work provides the mechanistic insights into how EA, a polyphenol ubiquitously 
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found in fruits and vegetables, attenuates human adipocyte differentiation by altering 
chromatin remodeling.    
 
1. Introduction 
Epigenetic modification refers to the inheritable changes of gene expression in the 
absence of a change in the DNA sequence itself. Epigenetic modification comprises DNA 
methylation in CpG islands, covalent modification of histone tails, and noncoding 
microRNA-mediated gene silencing [1-6]. In particular, histone modification is a key 
mechanism in the switching on and off of genes for differentiation; N-terminal tails of H3 
and H4 interact with the negatively charged DNA backbone in unmodified states. Histone 
modifying enzymes target specific amino acids of histones, producing changes in 
acetylation, methylation, phosphorylation or ubiquitination status. Modifications of these 
histone codes alter chromatin conformation, which subsequently induce dissociation of 
transcriptional (co)repressors as well as recruitment of transcriptional (co)activators [7-
10]. In general, histone acetylation on lysine residues decreases chromatin compactness, 
increases accessibility to genes, and thereby induces transcriptional activation. Several 
transcriptional co-activators possess histone acetyltransferase (HAT) activity to transfer 
acetyl groups to lysine residues in histones, promoting conformational change in 
euchromatin structure [11-14]. In contrast, transcriptional co-repressors often possess 
HDAC activity to remove acetyl moieties from histone tails, leading to a less accessible 
heterochromatin conformation [15, 16]. Regulation of transcription by histone 
methylation is more complex than by histone acetylation. Histone methylation can be 
correlated with either gene activation or repression depending on histone residues (lysine 
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or arginine), specific genetic loci, or distinctive methylation pattern (e.g., asymmetric or 
symmetric) [17-21]. 
A growing body of literature has revealed that epigenetic regulation is a key 
mechanism for adipocyte differentiation. Although considered controversial, an increase 
in global histone acetylation is preceded by adipocyte differentiation as the consequence 
of decreased HDAC activity [22]. More specifically, H3 acetylation at lysine 9 
(H3K9Ac), and H3 methylation at lysine 4 (H3K4Me2) have been implicated for positive 
regulation of adipocyte differentiation [23]. The obligatory suppression of Wnt signaling 
is also regulated by chromatin modification via H3 lysine 27 (H3K27Ac vs. H3K27me3) 
[24]. Several histone modification enzymes, e.g., protein arginine methyltransferase 4 
(PRMT4 also known as coactivator-associated arginine methyltransferase 1 (CARM1)) 
[25], PRMT5 [26], histone methyltransferase G9a [27], and HDAC9 [28], have been 
identified as either positive or negative regulators for adipocyte differentiation. Moreover, 
recent advances in  chromatin immunoprecipitation (ChIP) methodology has revealed 
that activation of transcriptional cascade networks during early adipogenesis coincides 
with the regulation of histone modification of key transcription factors such as 
peroxisome proliferator-activated receptor gamma (PPAR [25]. These studies have 
clearly demonstrated that chromatin remodeling dictates adipocyte differentiation. 
However, less information is available whether environmental effectors are able to 
reprogram epigenetic codes for adipocyte differentiation. Interestingly, accumulating 
evidence suggests that our daily diet is an important epigenetic determinant regulating 
obesity. Exposure to a HF-diet early in life can alter chromatin structure, leading to an 
increased risk of obesity in adulthood [29-31]. Conversely, consumption of fruits and 
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vegetables (FV) is inversely associated with obesity [32]. It is largely unknown whether 
epigenetic regulation could be a viable mechanism to explain reduced adiposity by FV 
consumption. By displacing energy-dense foods, FV consumption increases satiety, 
decreases food intake, and therefore induces weight loss [33]. Besides this satiety effect, 
it is plausible to hypothesize that FV contain principle phytochemicals that can modulate 
the activity of chromatin-modifying enzymes, thereby reducing adiposity. Recently, our 
group has reported that supplementation of muscadine grape phytochemicals (MGP) 
decreased visceral obesity and obesity-mediated metabolic complications without altering 
food intake [34]. Among the polyphenolic compounds of MGP, EA has identified as the 
most potent polyphenol in inhibiting adipogenic conversion (under review).  These 
studies led us to raise the question of whether EA regulates epigenetic regulatory factors 
in adiposity. Here, we present evidence that EA, a polyphenol commonly found in many 
FV, attenuates adipocyte differentiation by modulating histone arginine methylation and 
subsequent histone acetylation levels. 
 
2. Materials and Methods  
2.1. Materials  
All cell culture dishes were purchased from Fisher Scientific. Fetal bovine serum 
(FBS) was purchased from Cellgro. Rosiglitazone (BRL49653) was purchased from 
Cayman Chemical. All other chemicals and reagents were purchased from Sigma 
Chemical Co., unless otherwise stated.  
2.2. Preparation of human adipogenic stem cells (hASCs) and adipogenic differentiation 
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Abdominal adipose tissue was obtained from females with a body mass index (BMI) 
of ~30 during liposuction or abdominal plastic surgeries. Isolation of hASCs and 
differentiation of adipocytes were conducted as described by Skurk et al. [35]. All 
protocols and procedures were approved by the Institutional Review Board (#693-2011) 
at the University of Florida. After removing initial monocytic cells (selective adherence 
to plastic), the released stromal vascular fractions were passaged down no more than 
three times. These  adipogenic stem cell rich stromal vascular (SV) fractions are regarded 
as human adipogenic stem cells (hASCs) without further purification procedures [36]. A 
pool of hASCs from three or four different human subjects was used for each experiment 
to avoid individual variation. Conditions for hASCs proliferation and differentiation were 
described previously [37, 38]. Ellagic acid (E2250, Sigma) stock was prepared in 
dimethyl sulfoxide (DMSO); aliquots of stock (10 mmol/L) were kept at -20 ̊C and 
freshly diluted at the time of addition to hASCs. For induction to adipogenic 
differentiation, cells were seeded (5 × 105/cm2) in 35mm plates and allowed to attach for 
24 hours in proliferation medium. After attachment, cultures were grown for the next 3 
days in differentiation medium containing 0.25 mmol/L isobutylmethylxanthine, 1 
μmol/L rosiglitazone, and 500 nmol/L human insulin in commercially available human 
adipocyte medium (AM-1, ZenBio). Adipocyte medium (AM-1) was replenished every 3 
days. Under these conditions, cultures of hASCs were induced to differentiation in the 
presence of 10 μM EA or DMSO (vehicle) for seven days. The presence of intracellular 
lipid accumulation was visualized by oil red-O (ORO) staining.   
 
2.3. qPCR and microarray analysis  
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Gene-specific primers for qPCR were obtained from Integrated DNA Technologies 
(Chicago, IL). Total mRNA of hASCs was isolated using Trizol reagent (Invitrogen). To 
remove genomic DNA contamination, mRNA was treated with DNase (Mediatech); 2 μg 
of mRNA was converted into cDNA in a total volume of 20 l (iScript cDNA synthesis 
kit, Bio-Rad). Gene expression was determined by real-time qPCR (CFX96, Bio-Rad), 
and relative gene expression was normalized by the average of two reference genes, 36B4 
and/or GAPDH (primer sequences will be available upon request). The complete gene 
lists can be found in Supplemental Table 1. For PCR microarray analysis, RT
2
 profiler 
PCR array for Human epigenetic chromatin modification enzymes (QIAGEN, PAHS-
085Z) was used according to the manufacture’s protocol. For each group, pools of equal 
amounts of total mRNA provided from four different human subjects were used. The 
results were analyzed using software provided by QIAGEN 
(http://www.sabiosciences.com/pcrarray data analysis.php#Excel). 
 
2.4. Western blot analysis 
To prepare total cell lysates, monolayers of differentiated cultures of human 
adipocytes were harvested with ice cold RIPA buffer (Thermo Scientific) with protease 
and phosphatase inhibitors (Sigma). For nuclear extract preparation, NE-PER nuclear and 
cytoplasmic extraction kit (Thermo Scientific) was used according to the manufacturer's 
protocol. Proteins were fractionated onto 4-15% pre-casted SDS-PAGE (Biorad), 
transferred to PVDF membranes with a semi-dry transfer unit (Hoefer TE77X), and 
incubated with the relevant antibodies. Chemiluminescence from ECL solution (Western 
Lightning) was detected with FluorChem E (Cell Biosciences) imaging system. 
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Polyclonal or monoclonal antibodies targeting to β-actin (4967), H3K9Ac (AcH3, 9649), 
HDAC1 (5356), HDAC2 (5113), HDAC3 (3949), HDAC4 (7628), HDAC5 (2082), 
HDAC6 (7558), AcH4 (2594), H3K27Ac (4353), H4 (2935), lamin A/C (4777), CARM1 
(3379) were purchased from Cell Signaling Technology. Antibodies to HDAC9 (ab 
59718), and histone H3 (ab1791) were purchased from Abcam. PPAR(sc-7273) and 
FABP (aP2, sc-271529) were purchased from Santa Cruz Biotechnology. The polyclonal 
antibody for detecting histone 3 asymmetric-dimethyl Arginine 17 (H3R17me2, NB21-
1132) was purchased from Novus Biotechnology. 
2.5. HDAC enzyme activity assays 
Total cellular histone deacetylase enzymatic activity was measured using a 
commercial HDAC assay kit (Upstate Biotechnology) according to the manufacturer’s 
protocol. Briefly, 30 g of nuclear lysate were incubated with fluorescent substrate in 
HDAC assay buffer for 45 minutes at 30 ̊C. An activator solution was added to release 
the fluorophore from the deacetylated substrates, and fluorescence was measured in a 
multichannel fluorometer (Synergy H1, Biotech). 
2.6. Depletion of HDAC9 using siRNA 
For silencing HDAC9, hASCs were seeded at confluent density and allowed to attach 
for 24 hours in a proliferation medium. Culture of hASCs were transfected with either 
200 nmol/L of human HDAC9 ON-TARGET plus SMART pool siRNA (Thermo 
Scientific) or 200 nmol/L non-targeting control siRNA (Thermo Scientific) at 48 hours 
prior to adipogenic stimulation using DharmaFECT1 transfection reagent according to 
the manufacturer's protocol. The transfection efficiency was determined by Cy3-tagged 
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siGLO (Thermo Scientific). After 48 hours of transfection, hASCs were stimulated for 
differentiation in the presence and absence of EA during 72 hours (Fig. 3. A).  
2.7. Immunocytochemistry of H3R17me2 and HDAC9 
hASCs were cultured onto coverslips and immunostained for immunofluorescence 
microscopy as described previously [37]. Briefly, cells were fixed with 3.7 % 
paraformaldehyde for 20 minutes. After quenching paraformaldehyde with glycine, 
coverslips were permeabilized with ice cold Triton X-100 (0.1 %) and blocked with 1.25 
mg/ml normal goat serum for 1 hour. The coverslips were incubated overnight with 1:100 
dilution of the antibodies of H3R17me2 (ab8284) and HDAC9 (ab18970) antibody 
(Abcam) at 4 ̊C, followed by incubation for 1 hour with a 1:300 dilution of rhodamine 
red-conjugated goat anti-rabbit IgG (Jackson Immunoresearch). Fluorescent images were 
captured using a digital inverted fluorescence EVOS microscope (AMG Inc.). DAPI 
staining was used for counter-staining of the nucleus.   
2.8. Cell permeable peptide-CARM1 (CPP-CARM1) 
Purified CPP-CARM1 was a generous gift from Dr. Dong Ryul Lee at the CHA 
University in South Korea [39]. CPP-CARM1 (2 g/mL) was delivered to hASCs 24 
hours prior to adipogenic stimulation with or without EA. This allows sufficient time for 
CPP-CARM1 to translocate into the nucleus before hASCs are exposed to EA. Every two 
days, fresh CPP-CARM1 was added during routine media changes.   
2.9. Statistics 
All data are presented as the mean ± SEM. The data were statistically analyzed using 
a Student’s t-test or one-way ANOVA with Tukey’s multiple comparison tests. All 
analyses were performed with GraphPad Prism 5 (Version 5.04).  
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3. Results 
3.1. EA alters HDAC9 expression and HDAC activity during adipocyte differentiation 
Recently, we have identified that EA is most potent polyphenols that exerts the anti-
adipogenic property (under review). To gain an insight into whether EA regulates 
epigenetic factors of adipogenesis, we performed qPCR microarrays for chromatin 
modification enzymes. Among the 84 genes that regulate chromatin accessibility to 
genomic DNA or histones (by altering the status of acetylation, methylation, 
phosphorylation or ubiquitination), 10 genes were upregulated (> 2 fold) by EA treatment 
without any specific genes being significantly downregulated (< 2 fold) (Fig 1A, also see 
Supplemental Table 2). In particular, HDAC9 gene expression levels were ~20 fold 
higher than that of vehicle control. To validate the array results, HDAC gene expression 
was measured using individual gene-specific primers. As we expected, no difference was 
found in Class I (HDAC 1, 2, 3, 4, and 8) or Class III HDAC genes between EA-treated 
vs. control human adipocyte samples. In parallel to results from the qPCR array, HDAC9 
gene expression was specifically higher in EA-treated adipocytes compared to vehicle 
controls among the Class II DAC genes (HDAC 5, 7, 9, 10). Interestingly, for HDAC11, 
a class IV HDAC enzyme, mRNA levels were also significantly higher than control (Fig 
1B). HDAC9 protein levels were higher in EA-treated nuclear fraction, while other 
HDAC protein levels were similar between the two groups (Fig 1C).  
Next, we examined whether EA also alter HDAC activity and histone acetylation 
levels. There was a < 50% reduction of global HDAC activity during the early 
differentiation period (4 days after exposure to differentiation stimuli), which was almost 
completely dampened in cultures grown with EA (Fig 2A). In the presence of 100 nM 
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trichostatin A (TSA), a pan-HDAC inhibitor, there was an additional decrease of HDAC 
activity in the nuclear extract of differentiated cultures; only ~10% of HDAC activity 
remained in comparison to undifferentiated hASCs (Fig 2B, the second bar). In contrast, 
EA-treated nuclear extracts still possessed 50% of HDAC activity in the presence of TSA 
(Fig 2B, the last bar). Consistent with the literature [22, 24], differentiation of hASCs 
significantly increased acetylation levels of H3K9Ac, H3K27Ac as well as AcH4 (Fig 
2C, left panel). Intriguingly, differentiation of hASCs with EA remarkably decreased 
histone acetylation levels (Fig 2C, right panel). To answer the question of whether the 
inhibition of HDAC activity is able to reverse the inhibitory effects of EA on 
adipogenesis, TSA was added to the hASCs along with EA. Consistent with results from 
Chatterjee et al. [28], the addition of TSA during the adipocyte differentiation procedures 
did not inhibit adipogenesis (Fig 2D, upper panel). Similarly, addition of TSA to EA-
treated cultures during adipocyte differentiation failed to restore both adipocyte 
morphology (Fig 2D) and PPAR expression (Fig 2E). Notably, HDAC9 gene expression 
was even higher with TSA treatment, suggesting that HDAC9 expression is not regulated 
by TSA-sensitive HDAC activity (Fig 2E). These results collectively demonstrate that: 1) 
EA inhibits downregulation of HDAC activity, presumably the TSA-insensitive portion; 
and 2) chemical inhibition of HDAC activity by TSA was unable to reverse EA-mediated 
HDAC9 expression as well as inhibition of adipogenesis.  
3.2. Silencing of HDAC9 is not sufficient to reverse the reduction of adipocyte 
differentiation by EA 
It has been shown that HDAC9 is a transcriptional co-repressor of adipogenesis by 
preventing the activation of C/EBP [28]. Our next question was whether the knockdown 
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of HDAC9 could reverse the anti-adipogenic effects of EA. To address this question, we 
used siRNA to deplete HDAC9. Transfection efficiency of hASCs was > 90 % estimated 
by Cy3-tagged non-targeting siGLO (data not shown). To knockdown HDAC9, 200 
nmol/L of siCont (non-targeting) or siHDAC9 were transfected with hASCs for 48 hours 
followed by adipogenic differentiation for 72 hours (Fig 3A). Transfection of siHDAC9 
attenuated HDAC9 gene expression approximately ~70% compared to siCont (Fig 3B), 
which remained constant throughout the experiment (data not shown). Reduction of 
HDAC9 protein levels in nucleus by siHDAC9 was comparable to siCont transfected 
cells without EA control (Fig 3C). Surprisingly, a substantial decrease of HDAC9 by 
siHDAC9 had minimal impact on EA-mediated suppression of adipogenic gene 
expression, C/EBP and PPAR or on H3K9 acetylation (Fig 3B, C). These data showed 
that reduction of HDAC9 was unable to reverse inhibition of adipogenesis by EA. 
Additionally, this implicates that additional regulatory factor(s) might be involved in the 
suppression of adipocyte differentiation by EA other than HDAC9 regulation per se.      
3.3. Inhibition of CARM1 by EA plays a key role in suppressing adipogenesis  
Recently, EA has been identified as a novel inhibitor for CARM1 [40], whose activity 
is required for asymmetric transfer of two methyl groups to the H3R17me2 (Fig 4A). 
Consistently, immunostaining of differentiated human adipocyte cultures (heterogeneous 
culture containing ~50 % adipocytes) with an H3R17me2 antibody showed that CARM1 
activity is restricted to lipid-laden adipocytes, but not in undifferentiated hASCs (Fig 4B). 
To further determine whether inhibition of CARM1 activity by EA would be a key 
mechanism to block hASCs differentiation, we examined the H3R17me2 levels during 
differentiation with or without EA incubation. Supporting the important role of CARM1 
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activity in adipocyte differentiation, EA treatment significantly reduced H3R17me2 
levels compared to vehicle control from the nuclear extract fraction used in Fig 1C (Fig 
4C). However, there was no significant difference in mRNA or protein levels of CARM1 
(Fig 4C, D), suggesting that EA inhibits enzyme activity of CARM1 rather than by 
transcriptional or translational modification of CARM1.  
If the inhibition of CARM1 activity by EA is the major mechanism to block 
adipogenesis, the replenishment of CARM1 activity can rescue adipocyte differentiation. 
To test this concept, 2 g/mL of recombinant cell penetrating peptide CARM1 (CPP-
CARM1) [39] were added to hASCs throughout the adipogenic differentiation with 10 
mol/L EA. Although adipocyte morphology was not completely restored, addition of 
CPP-CARM1 substantially increased TG accumulation compared to EA only treatment 
assessed by ORO-staining (Fig 5A). Accordingly, co-stimulation of CPP-CARM1 with 
EA significantly increased PPAR gene and protein level compared to EA treatment 
alone (Fig 5B, C). The restoration of CARM1 activity by addition of CPP-CARM1 also 
increased H3R17me2 and H3K9 acetylation levels (Fig 5C). Moreover, immunostaining 
of HDAC9 revealed that addition of CPP-CARM1 reduced EA-mediated retention of 
HDAC9 in nucleus (Fig 5D). Taken together, these data strongly suggest that inhibition 
of H3R17me2 by EA is the key step to repress the subsequent H3K9 acetylation, HDAC9 
dissociation from chromatin, and PPAR activation. 
 
4. Discussion  
White adipose tissue (WAT) is not only a storage organ for surplus energy, but is also 
active endocrine tissue critical in energy and glucose homeostasis [41-43]. The metabolic 
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and endocrine function of adipocytes correlate to the dynamics of adipocytes, i.e., 
adipocyte size and numbers [44]. Plasticity of the adipocytes seems to be dictated by 
chromatin remodeling and transcriptional networks in response to environmental 
effectors such as diet [45, 46]. Currently, little is known about the regulatory role of 
dietary polyphenols on epigenetic remodeling in adipocyte. The goal of this study was to 
identify potential links between dietary EA and epigenetic regulation of adipogenesis. We 
demonstrated that EA, a ubiquitous polyphenol in fruits and vegetables, inhibits 
adipocyte differentiation through CARM1-mediated epigenetic modification. Based upon 
our results, we propose the following working model (Fig 6): uncommitted hASCs are 
associated with high levels of HDAC9 that repress transcriptional activation of 
adipogenic genes [28]. Upon adipogenic stimuli, CARM1 enzyme facilitates the transfer 
of two methyl moieties to H3R17, which is accompanied by a subsequent H3K9 
acetylation and HDAC9 dissociation. In the presence of EA, inhibition of CARM1 
activity by EA results in suppression of H3R17 methylation, which in turn abolishes 
H3K9 acetylation and HDAC9 dissociation, and ultimately represses adipogenesis.  
Extensive research from several groups has identified that histone modifying enzymes 
play pivotal roles in adipocyte development: 1) Deletion of histone methyl-transferase 
enhancer of zeste homolog (Ezh2) abolished trimethylation on H3K27 of Wnt promoter 
region, resulting in constitutive activation of Wnt signaling and transcriptional inhibition 
of adipogenesis [24]; 2) Silencing of PRMT5 repressed adipogenic gene expression, 
which was reversed by PRMT5 overexpression [26]; 3) Histone methyltransferase G9a 
seemed to play dual roles for turning on or off adipogenic signaling based on its 
methylation sites by serving as either a co-activator or co-repressor [47]; 4) Class II 
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HDACs have been reported to control PPAR signaling [48]. Among the Class II HDACs, 
HDAC9 has been identified as a unique transcriptional co-repressor on C/EBP promoter 
[28]; and 5) Mice born with the deletion of CARM1 lacked in fat pad development [49, 
50], identifying the adipose specific role of CARM1 as a coactivator for PPAR [25].   
Despite accumulating evidence demonstrating the critical roles of individual histone 
modifying enzymes in adipogenesis, few studies have identified specific effectors that 
directly alter histone reprogramming by modulating histone modifying enzymes. In this 
study, we have identified that EA alters at least three distinctive epigenetic factors during 
adipogenesis of hASCs. 
The first modification that we immediately noticed was the abnormally high 
expression of HDAC9 via qPCR microarray of histone modifying enzymes (Fig 1). 
However, an increase of HDAC9 levels did not seem to be the major cause for EA-
mediated inhibitory effects on adipogenesis due to the following: 1) depletion of HDAC9 
upto ~70% had minimal effects on adipogenesis (Fig 3), suggesting the existence of anti-
adipogenic regulatory factor(s) occur ahead of the inhibition of HDAC9 downregulation; 
and 2) the possibility that EA increases HDAC9 activity does not seem to contribute anti-
adipogenic effects of EA. If HDAC9-mediated HDAC activity is the key mechanism to 
inhibit adipogenesis, inhibition of HDAC9 activity by TSA (it has been shown that 
HDAC9 activity is inhibited by TSA treatment [22]) should restore adipogenic potential, 
which was not the case in our experiment (Fig 2D, E). These results are consistent with 
conclusion from Chatterjee et al [28] demonstrating that HDAC9 represses the 
adipogenic transcription factor in a deacetylase-independent mechanism. Based on our 
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observations, EA seems to cause an earlier modification before the HDAC9 dissociation 
step, which is necessary but not sufficient to initiate adipogenesis. 
The second modification that we noticed was decreased histone acetylation levels and 
increased HDAC activity by EA (Fig 2A, C). The role of histone acetylation on 
adipogenesis seems to be inconsistent; inhibition of HDAC activity by TSA inhibits 
adipogenesis in 3T3-L1 cells [22], while it fails to inhibit adipogenesis in primary 
adipogenic precursor cells in mice and humans [28]. One thing we confirmed is that 
TSA-sensitive HDAC activity is not required for adipogenesis at least in hASCs ([28], 
our data Fig 2). Thus, downregulation of the TSA-insensitive portion of HDAC activity 
might be critical to initiate adipogenic differentiation. This is based upon our data 
showing that EA treatment during adipogenesis almost completely blocked the 
adipogenic cocktail-mediated HDAC activity; also that a significant amount of HDAC 
activity remained even with TSA treatment without promoting adipogenesis (Fig 2). 
Conversely, it indicates that downregulation of TSA-insensitive HDAC activity may be 
required for adipogenesis. Intriguingly, we did not find any evidence that EA directly 
alters HDAC or HAT activity (data not shown). This is also consistent with the report 
from Selvi et al. [40]. Although the mechanistic link between EA treatment and ‘HDAC 
activity and histone acetylation status’ is uncertain, our results suggest that EA may 
inhibit earlier signals that could lead to global histone acetylation for facilitation of 
adipogenesis. 
 The third and the most fundamental epigenetic modification that we have identified is 
the attenuation of H3R17me2 levels by EA, due to reduced CARM1 activity (Fig 4). 
Yadav et al. have established the role of CARM1 as a PPAR coactivator in adipose 
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tissue [25], and Selvi et al. have reported the general effects of EA on CARM1 enzyme 
[40]. However, our work is the first to report that EA inhibits asymmetric dimethylation 
of H3R17 during adipogenic differentiation in hASCs by linking CARM1 activity to anti-
adipogenic effects of EA. It was unexpected to find that HDAC9 depletion could not 
restore H3R17me2 in the presence of EA in hASCs (Fig 3). This implies that the 
modification of CARM1 activity may precede the dissociation of transcriptional repressor 
HDAC9. It was important to note that regaining CARM1 activity by adding CPP-
CARM1 recovered HDAC9 dissociation from the nucleus, histone acetylation, as well as 
adipogenic gene expression and TG accumulation (Fig 4). These data clearly demonstrate 
that the modulation of CARM1 by EA is the key mechanism to inhibit successive 
epigenetic modification for adipocyte differentiation, i.e., releasing transcriptional 
(co)repressors. The exact mechanistic regulations collaboratively control methylation on 
H3R17, releasing HDAC9 from chromatin (probably from PPRE; PPAR response 
elements), and acetylation of histone are currently unknown. A recent work by Wu et al. 
demonstrated that arginine methylation on H3R17 and H3R26 by CARM1 is associated 
with discharging the transcriptional co-repressor NuRD, a nucleosome remodeling and 
the deacetylase complex, by facilitating histone acetylation in MEF cells [51]. This study 
supports our proposed model (Fig 6) in terms of connecting CARM1-mediated histone 
arginine methylation to the dissociation of HDAC activity-possessing transcriptional 
repressors and augmentation of histone acetylation.  
Although our proposed model has built upon the data obtained from human adipogenic 
progenitor cells (hASCs), it still contains limitation to apply to humans: 1) we used the 10 
mol/L of EA, which is difficult to be achieved in regular diets. Our unpublished data 
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showed that EA could be effective in inhibiting adipogenesis and altering histone 
acetylation with the concentration as little as 2.5 mol/L in hASCs. More information 
about optimal EA concentration to exhibit physiological effectviness in vivo is required; 2) 
current study does not include the information about EA metabolites. There is emerging 
evidence that EA-derived gut microbial metabolite urolithin A exerts various health 
benefits [52, 53]. Therefore, it needs to be determined whether urolithin A is also 
proficient in modulating epigenetic factors that are proposed in this study. To investigate 
nutritional significance of EA in vivo, we are currently conducting animal studies by 
feeding HF diet with or without EA supplementation. In addition, to further establish the 
adipose tissue-specific role of CARM1 on metabolic syndrome, we are under preparation 
to generate adipocyte specific knockout mice of CARM1.  
In conclusion, our present study provides mechanism-based evidence that EA 
attenuates adipogenesis and offers novel insights into targeting epigenetic modification 
for adipogenesis control using a dietary EA.   
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Figure III-1 EA alters HDAC9 expression during adipocyte differentiation. 
Cultures of hASCs were induced to differentiation in the presence of 10 μmol/L EA or 
DMSO (vehicle) for seven days. (A) Microarray analysis of human chromatin 
modification genes (84 genes) by qPCR from the hASCs treated with either 10 μM EA or 
vehicle for seven days during differentiation. Pooled mRNA from four different human 
subjects was used for analysis. Broken lines indicate 2-fold expression of differences 
between treatments. (B) Gene expression levels of Class I, II, IV of HDAC and sirt1 and 
2 (Class III) by qPCR. (C) Protein expression levels of HDAC 1, 2, 3, 4, 6 and 9 in 
nuclear extract. H3 and lamin A/C were used for loading control. * P< 0.05, *** P < 
0.001 by student’s t-test.  
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Figure III -2 EA alters HDAC activity during adipocyte differentiation. 
 (A) Nuclear HDAC enzyme activity in undifferentiated (Diff -) and differentiated (Diff +) 
adipocytes in the presence or absence of EA for four days. (B) HDAC activity with or 
without pan-HDAC inhibitor TSA (100 nmol/L). (C) Western blot analysis for detecting 
H3K9Ac and H3K27Ac and AcH4. H3, H4, lamin A/C were used for loading control and 
aP2 used as an adipocyte marker. (D) Phase contrast images of hASCs differentiated with 
either EA or TSA only, or co-treatment of TSA+EA for seven days. (E) PPARand 
HDAC9 gene expression grown in the presence or absence of TSA and EA. Data are 
expressed as the mean ± SEM from n = 4 samples of two separate experiments. Means 
are not sharing a common superscript differ by one-way ANOVA with Turkey's multiple 
comparison (p < 0.05).  
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Figure III -3 Depletion of HDAC9 in hASCs has minimal impact on EA-mediated 
inhibition of adipogenesis.   
 (A) Experimental scheme for depletion of HDAC9 before adipogenic differentiation 
with or without EA. hASCs were transfected with siCont or siHDAC9 at 48 hours before 
differentiation. Differentiated cultures were kept for 3 days before harvest of mRNA and 
protein after differentiation. (B) Relative gene expression of HDAC9, C/EBP and 
PPAR by qPCR analysis. (C) Protein levels of HDAC9, AcH3, H3R17me2, aP2, lamin 
A/C, and total H3 in siCont or siHDAC9 transfected cells. All values are presented as the 
mean ±SEM. * P < 0.05 by one-way ANOVA.     
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Figure III -4 EA inhibits H3R17me2 without affecting CARM1 expression levels.   
 (A) EA inhibits CARM1-mediated methylation of H3 arginine 17 in adipocytes. (B) 
Immunolocalization of H3R17me2 (red) and DAPI (blue). Differentiated hASCs were 
immunostained with H3R17me2 antibody and the nuclei were counterstained by DAPI. 
Phase contrast image (40X) was overlapped to distinguish lipid loaded adipocytes vs. 
undifferentiated cells. (C) Inhibition of H3R17me2 by EA without changes of CARM1 
protein levels. Lamin A/C were used for loading control and PPAR used as an adipocyte 
marker. (D) CARM1 gene expression measured by qPCR. Data are presented as the mean 
±SEM. ns= not significant by student’s t-test.  
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Figure III -5 Rescue of CARM1 activity by delivering CPP- CARM1 partially 
reverses EA-mediated adipogenesis of hASCs.   
CPP-CARM1 was delivered to hASCs at 24 hours prior to adipogenic differentiation then 
differentiation was induced in the presence or absence of EA for seven days. (A) TG 
accumulation was visualized by ORO-staining. Black boxes show magnified images. (B) 
PPARgene expression determined by qPCR. (C) Protein levels of H3R17me2, H3K9Ac, 
H3, and PPARby western blot analysis. (D) Immunostaining of HDAC9 was merged 
with DAPI staining to show decreased HDAC9 levels in CPP-CARM1 added cultures. 
Data are presented as the mean ±SEM., ** P < 0.001 by student’s t-test. 
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Figure III -6 Epigenetic modification of adipogenesis by EA through the mechanism 
involved in CARM1 inhibition in hASCs 
A working model illustrating the mism by which EA inhibits adipogenesis in hASCs. (A) 
Uncommitted hASCs are associated with high levels of HDAC9, a transcriptional 
corepressor of adipogenic genes. (B) Upon adipogenic stimuli (including HF diet and 
high insulin), CARM1 enzyme facilitates the transfer of two methyl moieties to H3 
arginine 17 sites (H3R17m2), which subsequently increases histone acetylation and 
HDAC9 dissociation from chromatin. (C) In the presence of EA, EA inhibits CARM1 
activity, which blocks subsequent epigenetic modification, resulting in transcription 
inactivation of adipogenic genes.     
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Abstract 
Chronic intake of high sucrose (HS) diet exacerbates high fat (HF) diet-induced obesity 
and its associated metabolic complications. Previously, we have demonstrated that ellagic 
acid (EA), an abundant polyphenol found in some fruits and nuts, exerts distinct lipid-
lowering characteristics in hepatocytes and adipocytes. In this study, we hypothesized 
that EA supplementation inhibits HS diet-mediated hepatic toxicity and its accompanied 
metabolic dysregulation. To test this hypothesis, C57BL/6 male mice were randomly 
assigned to three isocaloric HF diets (41 % calories from fat) containing either no-sucrose 
(HF), high-sucrose (HFHS), or high-sucrose plus EA (HFHS-R) from raspberry seed 
flour (RSF, equivalent to 0.03 % of EA), and fed for 12 weeks. The inclusion of EA from 
RSF significantly improved HFHS diet-mediated dyslipidemia and restored glucose 
homeostasis levels similar to the HF diet-fed mice. Despite marginal difference in hepatic 
triglyceride content, the addition of EA substantially reversed the activation of 
endoplasmic reticulum (ER) stress and oxidative damage triggered by HFHS diet in the 
liver. These effects of EA were further confirmed in human hepatoma cells by reducing 
ER stress and reactive oxygen species (ROS) production. Moreover, HFHS-R diet 
significantly decreased visceral adipocyte hypertrophy and adipose tissue inflammation 
evidenced by reduced pro-inflammatory gene expression and macrophage infiltration. In 
summary, EA supplementation from RSF was effective in reducing HFHS diet-mediated 
metabolic complication by attenuating hepatic ER and oxidative stresses as well as 
adipocyte inflammation. Our results suggest that the inclusion of EA in diets may 
normalize metabolic insults triggered by HS consumption.    
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1. Introduction 
Obesity is defined as a chronic low-grade inflammatory condition, which causes 
major health problems in the United States and many parts of the world [1]. The obesity 
epidemic appears to have emerged largely from the imbalance between energy intake and 
energy expenditure. The critical role of HF diets on the pathogenesis of obesity has been 
well-established over the past fifteen years [2, 3]. In addition to the positive correlation 
between obesity and HF diets, accumulating evidence pinpoints that consumption of high 
contents of sucrose (or fructose) is an independent metabolic risk factor to exacerbate 
obesity and its accompanied health complications [4, 5].   
Although it is controversial, the overall consumption of total sugar and sweeteners 
has increased in the United States over the past few decades [6, 7]. The surge of fructose 
into portal vein perturbs hepatic glucose and lipid metabolisms. High sugar intake is 
associated with reduced glucose uptake, elevated gluconeogenesis and hepatic glucose 
output, enhanced de novo TG synthesis, and promoted ER stress and hepatic 
inflammation [8]. These metabolic modifications appear to underlie the induction of 
insulin resistance commonly observed with HS feeding in both humans and rodent 
models of obesity. Moreover, epidemiological studies have revealed that sugar 
consumption is positively correlated with weight gain [7]. Given the deleterious 
contribution of HS intake to metabolic syndrome, there is an immense need for 
developing new strategies to counteract the HS diet-mediated metabolic insults. 
EA is a dietary polyphenol abundantly found in many fruits such as pomegranate, 
berries, muscadine grapes and mangos, as well as nuts [9, 10]. EA exhibits anti-
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proliferative, chemo-preventive, and anti-atherogenic properties in various cell types [11-
14]. The major mechanism of action of EA includes 1) inhibition of redox stress 
responses [15] and 2) attenuating inflammatory damage through the regulation of NF- B 
[16]. In addition, our group has identified that EA exerts lipid-lowering characteristics by 
inhibiting hyperplastic and hypertrophic expansion of adipocytes [17, 18], and by 
attenuating hepatic lipid accumulation [17]. Based on these unique properties, EA may 
downregulate the signaling modification triggered by HS diets, attenuating the attendant 
metabolic dysregulation. However, this possibility has not been investigated yet.   
The objective of this study is to explore the role of EA-containing RSF on HS 
diet-mediated hepatic toxicity and its metabolic consequences. To achieve this goal, we 
prepared three isocaloric HF diets containing no sucrose (HF), high sucrose (HFHS) and 
HS plus EA (HFHS-R) from RSF as a source of EA. Here, we report that inclusion of EA 
in HFHS diets was effective in reversing HS-mediated 1) ER and oxidative stress 
responses in liver and 2) adipocyte hypertrophy and pro-inflammatory responses in 
adipose tissue.  
  
2. Materials and Methods  
2.1. Chemical reagents  
All cell culture dishes were purchased from Fisher Scientific. Fetal bovine serum 
(FBS) was purchased from GIBCO. Pure EA (from tree bark) was purchased from Sigma 
Chemical Co. (#E2250). EA stock at 10 mM was prepared in dimethyl sulfoxide (DMSO) 
as described previously [17, 18]. Small aliquots of EA stocks were kept at -20 oC and 
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freshly diluted to 10 M with DMSO at the time of treatment in Huh7 cells. All other 
chemicals and reagents were purchased from Sigma Chemical Co., unless otherwise 
stated.  
2.2. Analysis of phenolic compounds in RSF 
Raspberry seed flour was purchased from Millennium©Health (Meeker Red 
Raspberry seed flour). For the analysis of phenolic compounds of RSF, 10 mg of RSF 
was extracted with 1 mL of methanol:DMSO:water (40:40:20) acidified with 0.1% HCl. 
The mixture was vortexed, subjected to ultrasonic bath for 10 minutes, and centrifuged at 
14,000g for 5 min in a Sigma 1-13 microcentrifuge (Braun Biotech. International, 
Germany). The supernatant was filtered through a 0.45 µm polyvinylidene difluoride 
(PVDF) filter. The sample was analyzed in an Agilent 1200 high-performance liquid 
chromatography (HPLC) system equipped with a ultraviolet-visible diode array detector 
(UV-Vis-DAD) (Agilent Technologies, Waldbronn, Germany) and an Esquire 1100 ion 
trap mass spectrometer (IT) with an electrospray interface (ESI) (Agilent). 
Chromatographic separation was carried out on a reverse phase Pursuit XRs C18 column 
(Agilent) (250x4 mm, 5 µm particle size) using water:formic acid (99:1, v/v) (A) and 
acetonitrile (B) as mobile phases. The gradient profile was: 0–20 min, 5–30% B; 20–30 
min, 30–55% B; 30–38 min, 55–90% B. This percentage was maintained for 2 min and 
then the column was equilibrated with the initial conditions for 8 min. A volume of 8 µL 
of sample was injected onto the column operating at room temperature and a flow rate of 
0.8 mL/min. The separated compounds were monitored in sequence with DAD (280 and 
360 nm) and with a mass spectrometry (MS) detector. Nitrogen was used as drying gas 
and nebulizing gas in the mass spectrometry detector with the following conditions: 
91 
 
 
 
nebulizer pressure 65 psi, dry gas flow 11 L/min, and dry gas temperature 350 ºC. Mass 
scan (MS) and daughter (MS-MS) spectra were measured in the m/z range of 100-1800 in 
the negative ionization mode. Phenolics were identified according to their UV and MS 
spectra, as well as MS/MS fragments. The extracts were chemically hydrolyzed as 
previously reported [19].  
2.3. Animal study 
Male C57BL/6 mice at six weeks of age were purchased from Jackson Laboratory 
(Bar Harbor, ME) and housed in a specific-pathogen free facility at the University of 
Nebraska-Lincoln. All animal experimental procedures were approved by the 
Institutional Animal Care and Use Committee at the University of Nebraska-Lincoln. At 
eight weeks of age, mice were randomly assigned to one of three experimental groups fed 
with different diets: isocaloric HF diets (41% calories from fat) containing either no-
sucrose (HF group), HS (HFHS group, 37% calories from sucrose), or HS plus EA 
(HFHS-R group) from RSF (equivalent to 0.03% of EA based on RSF analysis) and fed 
for 12 weeks. Diet preparation was adapted from the AIN-93G diets. For HFHS-R diet, 
cellulose was substituted for RSF (mainly dietary fibers), and thus the total dietary fibers 
among the diets were not different (Supplemental Table 1). Mice were given fresh ration 
every other day and fed ad libitum.  The daily food consumption per mouse was 
measured for 3 days at the last week of feeding before sacrifice. Changes in body weight 
(BW) of all mice were monitored weekly throughout the study (Supplemental Fig. 1).  
2.4. Cell culture and EA treatment 
Huh7 cells were maintained in Dulbecco’s modification of Eagle’s medium 
(DMEM) /Ham's F12 containing 1 mM glucose, 1% L-glutamine, 10% fetal bovine 
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serum, 100 units/mL penicillin, and 100 g/mL streptomycin in 5% CO2 at 37 °C. Huh7 
cells were seeded into 6-well plates (0.25×106) and pre-incubated with 10 M of EA for 
48 hours. To mimic the postprandial conditions of HFHS diet, Huh7 cells were 
challenged with mixtures of glucose (25 mM), fructose (50 mM) and palmitate-BSA 
complex (800 M) (Glc/ Fr/ PA).  
2.5. Measurement of blood biochemical parameters 
Enzymatic colorimetric assay kits were used to determine plasma levels of TG 
(Wako Diagnostics), total cholesterol (Roche Applied Sciences), and high-density 
lipoprotein (HDL) cholesterol (BioAssay Systems). Plasma low-density lipoprotein (LDL) 
cholesterol (mg/dL) was calculated from the Friedwald Equation [20]. Fasting blood 
glucose levels (mg/dL) were measured using a glucometer (Bayer, Contour). Commercial 
ELISA kit was used to determine plasma levels of insulin (Crystal Chem). 
2.6. Glucose and insulin tolerance tests 
A glucose tolerance test (GTT) was performed on overnight fasted C57BL/6 mice 
by intraperitoneal (i.p.) injection of 10% D-glucose solution (0.5 g/ kg BW). Blood 
glucose levels (mg/dL) were measured at 0, 15, 30, 60 and 120 min after injection using a 
glucometer (Bayer, Contuor). For insulin tolerance test (ITT), overnight fasted C57BL/6 
mice were administered 0.75 U/kg BW of insulin (Novolin R). Blood glucose levels were 
measured at 0, 10, 20, 30, 60 and 120 min after injection. The HOMA-IR (homeostasis 
model assessment of insulin resistance) index was calculated as [fasting plasma glucose× 
fasting plasma insulin/22.5] to assess insulin resistance. 
2.7. H&E staining, adipocyte size measurement and F4/80 staining. 
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Upon necropsy, liver and adipose tissues were dissected from the mice and 
immediately fixed in 10% buffered formalin. Tissues were embedded in paraffin, cut to 
5-7 micrometer sections, and processed for hematoxylin and eosin (H&E) staining as 
described previously [17]. H&E stained-sections of epididymal adipose tissue were used 
for size determination by following the published protocol by Chen et al. [21]. Briefly, 
adipocyte size was examined by analyzing digital images of H&E stained paraffin 
sections by using Image J software. For fluorescent immunohistochemistry (IHC)-F4/80 
staining, paraffin embedded adipose tissue sections were stained with a primary F4/80 
antibody (dilution 1:50, Abcam), followed by incubation with Alexa Fluor® 488 (Cell 
Signaling). Images were taken by using an EVOS microscope (AMG Inc.) 
2.8. Hepatic lipid accumulation  
The colorimetric triglyceride quantification kit (BioVision, K622‐100) was used 
to quantify the hepatic TG contents according to the manufacturer's protocol.  
2.9. Quantitative Real-Time PCR 
Gene expression analysis was performed as described previously [17]. Relative 
g
raw data to 36B4 (primer sequences in Supplemental Table 1).  
2.10. Western blotting analysis 
Snap frozen adipose and liver samples were homogenized with a polytron 
homogenizer (Elkhart, IN). Huh7 cell cultures were scraped in ice-cold radioimmune 
precipitation assay (RIPA) buffer (Thermo Scientific) with protease inhibitors and 
phosphatase inhibitor as described previously [22]. Proteins were separated using 8 or 10% 
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SDS-PAGE gels, transferred to PVDF membranes, and incubated with the relevant 
antibodies. Chemiluminescence was detected with ECL solution (PerkinElmer) using a 
FluorChem E system (Protein Simple). Polyclonal or monoclonal antibodies targeting 
phospho-JNK (4668), phospho-p38 (4511), phospho-eukaryotic translation initiation 
factor 2eIF2 (9721), phospho-Akt (Ser473, 4060), total Akt (9272) and -actin 
(4967) were purchased from Cell Signaling Technology (Danvers, MA). Phospho-insulin 
receptor substrate 2 (IRS2) (Ser388, 07-15171) or total-IRS2 (MABS15) were purchased 
from Invitrogen.  
 2.11. Measurement of hepatic oxidative stress 
For the determination of hepatic oxidative stress, liver tissue (50-100 mg) was 
homogenized. Amplex® Red Hydrogen Peroxide/Peroxidase Assay Kit (Invitrogen) were 
used to determine hepatic H2O2 content according to the provider’s instruction. To 
measure the intracellular accumulation of ROS in Huh7 cells, commercial kit of 2,7-
dichloro-dihydro-fluorescein diacetate (DCFDA) cellular ROS detection assay was used 
(Abcam). Briefly, Huh7 cells were pre-incubated with either DMSO or EA (0-40 M) in 
a dose-dependent manner for 2 days. Then, Huh7 cells were treated with Glc (25 mM), Fr 
(50 mM), and PA (800 M) with or without EA. After 12 hours later, Huh7 cells were 
washed with hanks' balanced salt solution (HBSS), and loaded with 20 μM DCFDA for 1 
hour at 37 °C. After 1 hour incubation, unincorporated dye was removed by washing with 
HBSS. Then 250 μM of H2O2 (t-butyl hydroperoxide (Sigma Aldrich)) was spiked to 
Huh7 cell with experimental conditioned media in the presence or absence of EA. 
Fluorescence intensity was measured by Synergy H1 (Biotech). Oxidation of DCFDA to 
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the highly fluorescent 2,7-dichloro-fluorescein (DCF) was proportionate to ROS 
generation. 
2.12. Inflammatory cytokine assay 
Homogenized epididymal adipose tissue and plasma were prepared for testing the 
levels of multiple inflammatory cytokines by using the Mouse Inflammation Array C1 
(Ray Biotech, Norcross, GA) according to the manufacturer's protocol. The complete 
blots were imaged by a FluorChem E System (Proteinsimple, Santa Clara, CA).  
2.13. Statistical analysis 
The data were statistically analyzed using one-way ANOVA analysis of variance 
with Tukey’s multiple comparison tests or Student’s t-test. All analyses were performed 
with GraphPad Prism 5 (Version 5.04). Results are presented as mean ± SEM.  
3. Results 
3.1. Raspberry seed flour (RSF) is a natural source of free EA and its precursors    
To investigate the potential role of dietary EA in normalizing the HS intake-
mediated metabolic complications, we prepared HFHS diet with or without EA from 
natural sources. We selected RSF as the source of EA as it has been reported to contain 
high levels of EA, ellagitannins (ETs), and its derivatives [23]. Our analysis shows that 
there were a negligible amount of anthocyanins or flavonols in RSF (Table 1). RSF 
mainly contained different proanthocyanidins (condensed tannins) and ETs (hydrolysable 
tannins), confirming that RSF was prepared from achenes of raspberries. Free EA content 
in the RSF was 1.1 mg/g whereas gallic acid was found only in trace amounts. To release 
the EA from tannins, RSF was hydrolyzed and neutralized for further analysis. After 
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hydrolysis, the amount of free EA increased up to 7 mg/g and gallic acid up to 0.39 mg/g 
(Fig. 1). In addition, valoneic acid dilactone (2 mg/g), another hydrolysis product of ETs, 
was also found upon hydrolysis. Based on this analysis, the maximally attainable EA 
contents by the ingestion of RSF (sum of parental compounds, EA and potential other 
metabolites) would be approximately 10 mg/g (1% in RSF). As we added 3 % of RSF to 
HFHS diet (Supplementary Table 1), we assume that total EA and its responsible 
derivatives in HFHS-R preparation would be equivalent to 0.03 % of EA. Furthermore, as 
the complete hydrolysis of ETs may not be achievable in vivo, we regarded HSHS-R as a 
source of EA no more than 0.03 % for the rest of the study.  
3.2. RSF supplementation attenuated HFHS diet-induced metabolic parameters 
and dyslipidemia in C57BL/6 mice 
We first investigated whether RSF supplementation alters HFHS diet-induced 
obesity. As seen in Table 2, there was no difference in food intake between the groups. 
After 12 weeks of the diet, mice fed with HFHS diet significantly promoted BW gain 
compared to mice fed with HF alone, which was partially normalized in mice fed with 
HFHS-R. Similarly, the extent to which HFHS diet promoted liver and visceral fat 
(epididymal and mesenteric) mass gain compared to HF diet, was partly attenuated by 
HFHS-R diet. However, liver/BW ratio did not reach statistical significance among 
groups despite the trend of stepwise decline in mice fed with HFHS>HFHS-R>HF. Next, 
we investigated whether the inclusion of RSF in HFHS diet improves plasma lipid 
profiles. As we expected both plasma TG and total cholesterol levels were higher in 
HFHS group than HF control. The elevated levels of TG and total cholesterol by HFHS 
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diet were almost completely dampened in HFHS-R group comparable to HF control. 
Consistently, decreased HDL cholesterol and elevated LDL cholesterol levels were 
restored in HFHS-R group close to the HF-fed control mice (Table 2). These data 
demonstrated that EA-containing RSF supplementation confers a resistance to HS-
mediated exacerbation of obesity and dyslipidemia.  
3.3. RSF supplementation normalized HS diet-mediated abnormal glucose 
metabolism 
Next, we asked whether RSF modulates HS-mediated abnormal glucose 
metabolism. As expected, HFHS fed mice exhibited higher fasting glucose and insulin 
levels than HF fed mice. Consistent with the improved plasma lipid profile by RSF 
(Table 2), inclusion of RSF decreased HS-mediated abnormal increase of blood glucose 
and insulin concentration to the levels of HF only group (Fig. 2A, B). The HOMA-IR 
index, an indicator of insulin resistance, revealed the HFHS-R fed group was 
approximately 3-fold more sensitive to insulin than HFHS group; sensitivities between 
HFHS-R fed group and HF fed group were similar (Fig. 2C). To confirm this, glucose 
(GTT) and insulin tolerance tests (ITT) were conducted. During GTT, glucose disposal 
was significantly slower in HFHS fed mice than HF fed mice. HFHS diet-mediated 
glucose tolerance was improved by RSF supplementation, which was confirmed by 
quantification of GTT area under curve (AUC) (Fig. 2D). In parallel, HFHS fed mice 
maintained higher glucose levels than HF fed mice during ITT. In contrast, glucose 
disposal rate between mice fed HFHS-R and HF alone was almost identical, showing no 
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difference in AUC (Fig. 2E). These data suggested that EA-containing RSF 
supplementation normalized the HS-induced glucose and insulin resistance in mice. 
3.4. RSF supplementation attenuated HS-mediated hepatic ER stress.  
HS intake has known to alter hepatic lipid metabolism and cause hepatic ER 
stress [24]. Given the significant improvement in plasma lipid profile by RSF (Table. 2), 
we hypothesized that RSF supplementation attenuates HS diet-induced hepatic steatosis 
and ER stress. The gross images of liver fed HFHS-R showed darker brownish color than 
HFHS fed liver, implicating that TG accumulation might be decreased. H&E staining of 
liver section revealed that TG accumulation appeared to be lower in HFHS-R fed group 
than HFHS fed mice (Fig. 3A). There was a decrease in TG content in HFHS-R fed group 
from HFHS, but it was not significant (Fig. 3B). It may reflect that HFHS-R diet showed 
a tendency to decrease liver mass compared to HFHS, but it was not significant (Table 2). 
Despite the marginal difference in liver mass, lipogeneic related gene expression of 
stearoyl CoA desaturase-1 (SCD-1), lipoprotein lipase (LPL) and diacylglycerol 
acyltransferases 2 (DGAT2) were markedly decreased in mice fed with HFHS-R 
compared to HFHS. However, hepatic gene expression levels of carbohydrate response 
element-binding protein (ChREBP) and sterol regulatory element-binding protein 1c 
(SREBP1c) did not differ between HFHS and HSHS-R fed mice (Fig. 3C). Intriguingly, 
the two genes promoting gluconeogenesis, glucose 6-phosphase (G6Pase) and 
phosphoenoylpyruvate carboxyl kinase (PEPCK) were also significantly down-regulated, 
suggesting that HS-mediated hepatic glucose output may be decreased by EA-containing 
RSF supplementation (Fig. 3D).  
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HS-mediated hepatic ER stress is associated with hepatic steatosis and 
upregulation of gluconeogenesis [25]. Thus, we determined the expression of ER stress 
markers in mice fed with HFHS vs. HFHS-R diet. RSF supplementation attenuated 
phosphorylation of JNK (p-JNK), p38 mitogen-activated protein kinase (p-p38 MAPK), 
and eukaryotic translation initiation factor 2A (p-eIF2) compared to HFHS feeding (Fig. 
3E). To validate these results in vitro system, we simulated ER stress condition in human 
hepatoma Huh7 cells by insulting cells with the combination glucose (Glc), fructose (Fr) 
and palmitate (PA). Pre-incubation of EA abolished the HFHS-triggered activation of p-
JNK and p-p38 in a dose-dependent manner (Fig. 3F). To determine whether EA 
attenuates HFHS-mediated inhibition of hepatic insulin signaling, basal and insulin-
stimulated phosphorylation of IRS-2 and Akt were measured in huh 7 cells (Fig. 3G). 
Huh 7 cells pre-treated with or without EA were simulated for ER stress by adding a high 
concentration of Glc, Fr and PA. Even in basal conditions, phosphorylation levels of IRS-
2 and Akt appear to be increased slightly in the presence of 10 M EA (Fig 3G, lane 1 vs. 
2). Insulin-stimulated p-IRS-2 and p-Akt were markedly higher in EA treated Huh7 cells 
(Fig 3G, lane 3 vs. 4), indicating that EA protects insulin signaling pathways against 
HSHS-mediated ER stress.  
3.5. RSF supplementation attenuated hepatic oxidative stress.  
Prolonged ER stress leads to ROS production and causes oxidative stress [26]. 
We hypothesized that RSF supplementation reduces HFHS-mediated hepatic oxidative 
stress. To address this, we first determined the hepatic H2O2 levels (mol/ mg protein), 
an indicator of ROS production in liver, was significantly higher in mice fed with HFHS 
100 
 
 
 
diet compared to mice fed with HSHF-R and mice fed with HF diet alone, which showed 
similar values (Fig. 4A). To confirm the effects of EA on ROS production in vitro, we 
measured ROS production in the presence or absence of EA by measuring DCFDA 
fluorescence levels in Huh7 cells. The ROS production rate (DCFDA fluorescence) 
increased drastically upon stimuli with high concentration of Glc, Fr and PA cocktail, 
which was significantly decreased in EA pretreated cells (Fig. 4B, also see Supplemental 
Fig. 2 for kinetic production of ROS). Collectively these data suggest that EA in RSF 
may contribute to a reduction in HSHS-mediated hepatic ROS production. 
3.6. RSF supplementation attenuated the HS-mediated adipose tissue 
inflammation  
To determine whether inclusion of RSF alters HFHS diet-induced adipose tissue 
remodeling, we first examined morphological changes of epididymal fat. H&E staining 
of adipose tissue clearly revealed that HFHS diet promotes adipocyte hypertrophy and 
macrophage infiltration compared to isocaloric HF diet. Despite the marginal difference 
in visceral fat mass (Table 2), HFHS-R diet significantly decreased adipocyte size and 
immune cell infiltration compared to HFHS diet (Fig. 5A). The analysis of adipocyte size 
and distribution confirmed these morphological changes. HFHS-R diet normalized 
HFHS-mediated adipocyte size expansion (111.53 ± 1.09 vs. 95.37 ± 0.86, HFHS vs. 
HFHS-R) (Fig. 5B) nearer to the HF control. Similarly, adipocyte size distribution from 
HFHS-R fed mice was shifted toward smaller sizes similar to HF diet feeding (Fig. 5C). 
Reflecting the smaller and more insulin-sensitized adipocytes, plasma levels of 
adiponectin levels (Fig. 5D) as well as adiponectin gene expression (Fig. 5E) were 
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significantly higher with HFHS-R diet than HFHS diet. The proinflammatory gene 
expressions including IL-6, IL-8, F4/80 (a marker for monocytic cells), tumor necrosis 
factor  (TNF) and monocyte chemoattractant protein 1 (MCP-1) were significantly 
reduced in HFHS-R-fed adipose tissue compared to HFHS-fed adipose tissue (Fig. 5E). 
The decrease of macrophage infiltration by HFHS-R was also confirmed by 
immunostaining of F4/80 (Fig. 5F). Inflammatory protein profiles were also determined 
using the membrane-based inflammatory cytokine array in adipose tissue and plasma. 
HFHS diet decreased proinflammatory adipokine production from epididymal adipose 
tissue including leptin, C-X-C motif chemokine 5 (CXCL5), chemokine (C motif) ligand 
(XCL1), MCP-1, macrophage colony-stimulating factor (M-CSF), soluble tumour 
necrosis factor receptor 1 (sTNFR1), and sTNFR2 (Fig. 5G, upper) and decreased plasma 
levels of proinflammatory cytokines XCL1, MCP-1, M-CSF, sTNFR1, and sTNFR2 (Fig. 
5G, below). Collectively, these data demonstrated that EA-containing RSF 
supplementation attenuated HS diet-mediated adipose inflammation and as well as 
systemic levels of inflammation. 
  
4  Discussion 
Western diet, high in saturated fat and sugar, but low in fresh fruits and vegetables, 
is the primary culprit to increase the risk of obesity and its associated metabolic 
dysfunction. This study was specifically designed to test the hypothesis whether the 
inclusion of EA in HFHS diet reverses the HS-induced metabolic complications. Here, 
we demonstrated that addition of EA-containing RSF significantly normalizes HFHS-
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induced dyslipidemia (Table 2), enhances hepatic and systemic insulin sensitivity (Fig. 2, 
3), reduces hepatic ER and oxidative stress (Fig. 3, 4), and inhibits proinflammatory 
adipose tissue remodeling and adipose dysfunction (Fig. 5) in C57BL/6 mice. To our 
knowledge, this is the first study to report the previously unrecognized function of EA in 
attenuating high sugar intake-inducible metabolic dysfunction by alleviating hepatic 
stress and adipose tissue inflammation.   
Despite the numerous health beneficial effects of EA, low bioavailability is the 
biggest caveat for the practical use of EA [27]. However, a recent study has suggested 
that plasma concentrations of free EA in peripheral human plasma could be higher than 
previously expected (80 nM vs. 10 nM), and the concentrations of EA in liver tissues 
could also be relevant [28]. Furthermore, EA is extensively metabolized by gut microbes 
producing urolithins. Although there are several studies showing that urolithins may 
resemble metabolic characteristics of EA [29, 30], it is difficult to estimate the exact 
physiological contribution of urolithins to metabolism. Moreover, urolithin production is 
highly compounding with the individual variability of microbiome [31]. Prior to this 
study, we had conducted a pilot study by feeding HF diet with 0.1 % of pure EA from 
tree bark (unpublished data). To our disappointment, we were not able to observe 
physiological benefits that we proposed in our cellular studies [17, 18]. We speculated 
that free EA consumption may dilute the EA’s health benefits due to its insolubility or 
prompt microbial conversion into urolithins. In this study, our criteria for selecting EA 
source were, 1) to use natural dietary source  (ET form) rather than synthetic EA or 
isolated EA from tree bark, 2) to avoid complete conversion into urolithins before 
absorption, and 3) to minimize the other bioactive polyphenolic contamination to isolate 
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the role of EA. RSF appeared to fit our experimental requirements because 1) raspberry is 
an affordable fruit with easy access, 2) RSF contains very few other polyphenolic 
compounds (Table 1), and 3) the ratio of free EA to EA precursors (mostly ETs) was 
roughly 1:6 (based on before and after hydrolysis of RSF), which may allow sufficient 
time to be released from tannin and absorbed in the gut, delaying microbial action. 
Supporting our rationales, Kosmala et al. has recently analyzed the chemical composition 
of raspberry vs. strawberry seeds; the main component of raspberry seed was fiber and 
the major polyphenols were polymerized ETs (dimer or trimer), while strawberry seed 
mainly composed of monomers of ET [23]. Proanthocyanidins (condensed tannin), the 
other polyphenolic compounds found in RSF, were relatively low compared to ET-
containing compounds [23]. Furthermore, the concentrations to exert bioactivity (lipid 
lowering and anti-inflammation) of depolymerized proanthocyanidins were in range of 
50-100 g/mL in vitro (our unpublished data), whereas EA is in 10 uM (2.7 g/mL) [17, 
18]. Therefore, RSF effects are likely due to combinatory of EA, ET, and its metabolites 
rather than other phytochemicals. In accordance with our results, raspberry ETs was more 
effective in lowering plasma TG levels than that of strawberry seed, suggesting that 
degree of conjugation with tannin (dimer/trimer>monomer> free EA) might regulate 
bioavailability of EA [23].  
A growing body of evidence suggests that there is a substantial link between HS 
consumption and metabolic dysfunction including non-alcoholic fatty liver diseases 
(NAFLD), obesity, dyslipidemia, and insulin resistance (sugar toxicity) [8, 32]. To test 
the central hypothesis that EA inhibits sugar toxicity, we prepared HFHS diets with and 
without RSF and compared their metabolic markers with isocaloric HF diet with no 
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sucrose. The inclusion of RSF in HFHS diet was associated with at least three metabolic 
outcomes attenuating 1) obesity and dyslipidemia, 2) hepatic ER/oxidative stress and 3) 
adipose inflammation.   
The first systemic metabolic benefit that we immediately noticed after RSF 
supplementation was the improvement of dyslipidemia and insulin sensitivity against 
HFHS diet (Table 1 and Fig. 1). Numerous studies in experimental animals and humans 
(both epidemiological and clinical intervention studies) have established that 
consumption of high-fructose promotes obesity, dyslipidemia (increased in plasma TG, 
LDL cholesterol, but decreased in HDL cholesterol) and insulin resistance [8, 33]. In 
agreement with this notion, switching carbohydrate source from dextrin (HF) to sugar 
(HFHS) without altering total calories, effectively promoted weight gain, dyslipidemia, 
and insulin resistance. These sugar toxicity-mediated metabolic abnormalities were 
ameliorated in the presence of RSF (Table 1). As RSF contains few other bioactive 
phytochemicals, the improvement of lipid profile and insulin sensitivity must be 
originated from EA and its derivatives in RSF. It is supported by growing evidence that 
consumption of EA-containing fruits protects high fructose-mediated metabolic abnormal 
modifications [34, 35]. The most noticeable benefits by RSF was a normalization of HS-
mediated elevation of total and LDL cholesterol (Table 2). It implicates that RSF may 
promote LDL catabolism. In fact, HFHS diet reduced hepatic LDL receptor (LDLr) 
resulting in an accumulation of LDL particles while inclusion of EA in HFHS diet 
upregulated LDLr and apoA-I (Supplemental Fig. 3). In agreement with our results, 
Yoshimura et al. showed that EA effectively upregulates LDLr gene expression in 
diabetic KK-Ay mice [36]. Several papers reported that either free EA or EA (or ET)-
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containing berries improve glucose and insulin tolerance against diet-induced obesity [35, 
37]. As an underlying mechanism, it has been suggested EA and gallic acid selectively 
inhibit -glycosidase, suppressing entry of monosaccharides from the lumen to intestinal 
epithelium [38]. If the inhibition of -glycosidase enzyme activity by RSF was the key 
mechanism to reduce plasma glucose level, HFHS-R-fed mice may exhibit lower blood 
glucose than HF-fed mice, because HF diet contains the same amount of -glycosidase 
bondages with HFHS-R. However, it does seem to be the case since RSF 
supplementation improved the only HS-mediated metabolic abnormality (comparable 
with HF only group). However, at this point, we do not entirely exclude the possibility 
that inhibition of -glycosidase by RSF contributes to the improvement of insulin 
tolerance against sugar toxicity. Unexpectedly, the apparent improvement in dyslipidemia 
and insulin sensitivity with 0.03% of EA supplementation was not directly correlated 
with the decrease in BW or adipose tissue weight; HS-mediated weight gain was 
significantly (p<0.05) reversed by RSF but to a lesser magnitude. We assume that 
modulation of adiposity may require a higher concentration of EA than controlling 
insulin sensitivity or plasma lipids. Taken together, the inclusion of no more than 0.03 % 
of EA in HFHS diet (roughly 30 mg EA /kg BW/day or ~1.8 g/60 kg BW) substantially 
reversed sugar-mediated insulin resistance and dyslipidemia. We believe that RSF-
mediated normalization of glucose tolerance would be the consequences of alleviated 
metabolic stress primarily from liver. 
Subsequently, we examined the potential benefit of RSF against sugar toxicity in 
the liver, the primary metabolic target organ for sugar toxicity. There is convincing 
literature demonstrating that HS intake promotes hepatic lipogenesis. It is due to unique 
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properties of fructose metabolism that 1) fructose is mostly metabolized in liver (about 80% 
in contrast to only 20% for glucose) [39], 2) entry of fructose into hepatic glycolysis 
bypasses the regulatory control of phosphofructokinase (PFK) producing unregulated 
lipogenic and proinflammatory precursors [39], and thus 3) fructose activates lipogenic 
transcription factors of SREBP1c, and ChREBP [25] leading to ER stress and insulin 
resistance. Furthermore, high fructose intake also impedes fatty acid oxidation and 
augments very-low-density lipoprotein (VLDL) secretion expediting hepatic lipid 
accumulation and systemic obesity [40]. Complying with metabolic modification by HS 
intake, our results showed that HFHS diet was associated with a 2-fold increase of 
hepatic TG deposition and significant upregulation of both lipogenic transcription factors 
(SREBP1c and ChREBP) and their target genes compared to isocaloric HF diet. 
Unexpectedly, hepatic TG contents were not apparently different between mice fed with 
HFHS and HFHS-R. These results are conflicting with our previous in vitro study 
showing that EA attenuated hepatic TG accumulation by decreasing both de novo 
synthesis FA and its esterification [17]. However, it is notable that hepatic lipogenic gene 
expressions of SCD-1, LPL and DGAT2 were downregulated in mice fed with HFHS-R 
compared to HFHS (Fig. 3C), despite insignificant differences in transcription factor 
levels of SREBP1c and ChREBP. More importantly, two critical regulators of 
gluconeogenesis and hepatic glucose output, G6Pase and PEPCK, were significantly 
lower in HFHS-R mice (Fig. 3D). This supports our finding that HSHF-R-fed mice were 
more glucose tolerant than HFHS-fed mice (Fig. 2). Augmented insulin sensitivity may 
be attributed to the decreased hepatic ER stress and ROS production (Fig. 3, 4). In 
agreement with our results, a few studies supported the notion that EA is capable of 
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scavenging free radicals and decreasing ROS production [41]. It is unclear why EA is 
more sensitive in repressing oxidative stress signaling than the transcriptional repression 
of lipogenic genes. It could be attributed to limited accessibility of EA to the nucleus or 
higher concentration of EA may be required for optimal regulation of gene regulation. 
Further studies should be conducted to validate these possibilities. Taken together, herein 
we report that EA supplementation by RSF could effectively suppress HS-induced 
hepatic ER stress, ROS production, and hepatic glucose output in the absence of an 
obvious reduction in hepatic TG content.  
Lastly, we assessed the impact of RSF on obesity and adipose tissue inflammation. 
The rank order of visceral adiposity among the mice fed with 12 weeks of isocaloric diet 
was, HFHS>HFHS-R>>HF, paralleling changes in body and liver weight. More 
importantly, there was a distinct improvement of adipose tissue remodeling by decreasing 
adipocyte size, immune cell infiltration and pro-inflammatory gene and protein 
expression (Fig. 5). Supporting our finding, the recent study by Winand et al. 
demonstrated that EA decreased TNF, IL-6 and chemokine (C-C motif) ligand-2 (CCL-
2) secretion in lipopolysaccharides (LPS) induced macrophage and adipocyte [42]. 
Notably, minor changes in adiposity by HFHS-R, promoted almost complete reversal of 
adipose tissue inflammation. At this point, it is unknown whether the reversal of HS-
mediated adipose tissue inflammation reflects role of EA in adipose tissue in situ, or 
indirect influence primarily from metabolic adaptation in liver (e.g., reduced VLDL 
secretion). We have previously reported that EA may impose direct lipid-lowering effects 
in human adipocytes. Several other studies have demonstrated that EA can impede 
adipocyte differentiation in vitro [43, 44]. Also, our preliminary work in human 
108 
 
 
 
adipocytes showed that urolithins are able to regulate adipogenesis or lipogenesis in vitro 
(unpublished). Future studies that analyze tissue levels of EA and its urolithin metabolites 
are necessary to identify whether EA or its metabolites urolithins directly target adipose 
tissue metabolism.  
In summary, here we tested an innovative idea whether inclusion of EA in HF diet 
could inhibit high sugar intake-mediated metabolic dysfunction. We identified that RSF, 
as a source of EA, effectively antagonized the effects of sugar toxicity including 
dyslipidemia, hepatic ER stress and ROS, and pro-inflammatory adipose tissue 
remodeling. Whether these initial findings in rodents will be confirmed in humans must 
await future studies. Nevertheless, we believe that our study shed new insight into EA-
containing foods consumption for the prevention of sugar toxicity.   
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Table IV-0-1 Main phenolic compounds identified in RSF. 
Compound Retention time m/z
-
 MS/MS 
Flavan-3-ol and 
proanthocyanidins 
   
Proanthocyanidin dimers 
(epi)catechin-(epi)catechin 
10.82; 12.33;14.82 577 451, 425, 407, 289 
(Epi)catechin (monomer) 11.76 289 271, 245, 161, 125 
Proanthocyanidin trimer 3 
(epi)catechin 
12.90 865 289 
Proanthocyanidin dimers 
(epi)afzelechin-(epi)catechin 
13.19; 14.26; 
15.25;17.06 
561 543, 435, 407, 289 
proanthocyanidin trimer 2 
(epi)catechin-(epi)afzelechin 
15.04 849  
Proanthocyanidin dimer 
(epi)afzelechin-(epi)afzelechin 
16.05 545 549,419,273,164 
Proanthocyanidin trimer 2 
(epi)afzelechin-(epi)catechin 
16.41 833  
Ellagic acid derivatives and ellagitannins 
*HHDP-hexoside 3.28 481 301 
bis-HHDP-hexoside 
(pedunculagin isomers) 
7.47; 9.52 783 481,301 
Castalagin/vescalagin isomers 8.52; 15.69, 16.70 
466 (double 
charged) 
865, 781, 631, 481, 
451, 301 
Galloyl-HHDP-glucose (corilagin 
isomers) 
8.91;9.69;11.42 633 481, 463, 301 
Valoneic acid dilactone isomers 8.98;11.54;14.20 469 425 
Digalloyl hexoside  10.60 483 331, 313, 271, 169 
Ellagitannin (unidentified) 13.50 
631 (double 
charged) 
938, 783, 695, 451, 
301 
Galloyl bis HHDP-glucoside 
isomers 
14.97;15.69;16.70, 
17.35 
467(double 
charged) 
751, 633, 451, 391, 
301 
Di-galloyl HHDP glucoside 15.25 785 633, 483, 301 
Ellagitannin (unidentified) 15.54 
551(double 
charged) 
765, 631, 448, 301 
Ellagic acid pentoside isomers 16.84;17.35 433 301 
Ellagic acid 18.28 301 257 
Phenolic acid derivatives     
Caffeoyl hexoside 2.51 341 179, 161 
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Table IV-0-2  Food intake, metabolic parameters and blood lipid profiles * 
Group
 
HF
 
HFHS
 
HFHS-R
 
p-value
 
Food intake 
(g/mouse/day)
 
3.43 ± 0.13
 
3.45 ± 0.13
 
3.27 ± 0.04
 
0.840
 
Phenotypes
     
BW (g)
 
36.67 ± 0.74 
b 
45.00 ± 0.59 
a 
40.50  ± 0.73 
ab 
0.011
 
∆ BW (g) 10.00 ± 0.46 b 18.5 ± 0.27 a 14.50 ± 0.77 ab 0.002 
Liver  (g)
 
1.57 ± 0.04 
b 
2.97 ± 0.18 
a 
1.97 ± 0.07 
ab 
0.046
 
Liver/BW (%)
 
4.27 ± 0.10
 
5.93 ± 0.49
 
4.86 ± 0.18
 
0.223
 
Epididymal fat (g)
 
1.82 ± 0.07 
b 
2.51 ± 0.048 
a 
2.14 ± 0.08 
ab 
0.040
 
Mesenteric fat (g)
 
0.60 ± 0.07 
b 
1.08 ± 0.07 
a 
0.88 ± 0.07 
ab 
0.015
 
Blood Chemistry    
 
Triglyceride (mg/dL)
 
25.59 ± 0.77 
ab 
38.93 ± 2.41 
a 
21.67 ± 2.07 
b 
0.056
 
Total Cholesterol 
(mg/dL)
 
110.33 ± 4.12 
b 
184.50 ± 2.36 
a 
122.83 ± 1.83 
b 
0.001
 
HDL (mg/dL)
 
71.28 ± 0.48 
a 
60.82 ± 0.22 
b 
72.13 ± 0.40 
a 
< 0.0001
 
LDL (mg/dL) 33.94 ± 0.48 
c
 115.80 ± 0.22 
a
 45.89 ± 0.40 
b
 <0.0001 
*
 Values are mean ± SEM. All groups, n = 6. Column not sharing a common letter are 
significantly different (p < 0.05) 
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Figure IV -1 Identification of ellagic acid and its derivatives after hydrolysis of RSF. 
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Figure IV-2  RSF supplementation ameliorated glucose and insulin tolerance in 
C57BL/6 mice against HS diet. 
Eight-week old male C57BL/6 mice were fed with isocaloric HF (grey), HFHS (white), 
or HFHS-R (black) diet for 12 weeks (n = 6 per group). (A) Fasting plasma glucose 
levels (mg/dL), (B) Fasting plasma insulin levels (ng/mL) quantified by ELISA, (C) 
HOMA-IR, (D) Glucose tolerance tests (GTT), (E) Insulin tolerance tests (ITT). Data are 
means expressed as mean ± SEM (n = 6). Bars with different letters are significantly 
different by one-way ANOVA. *P<0.05 (HF vs. HFHS), #P<0.01, and ###P<0.0001 
(HFHS vs. HFHF-R) by Student’s t-test. 
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Figure IV -3 RSF supplementation attenuated hepatic ER stress and insulin 
sensitivity against HS diet. 
Eight-week old male C57BL/6 mice were fed with isocaloric HF (grey), HFHS (white), 
or HFHS-R (black) diet for 12 weeks (n=6 per group) (A-E). (A). Gross images and 
representative microscopic images of liver revealed by H&E staining after 12 weeks of 
feeding with HFHS or HFHS-R, (B) Hepatic TG contents (mg/g liver), (C) Hepatic 
mRNA expression of  SCD-1, LPL, DGAT2, ChREBP and SREBP1c by qPCR, (D). 
Hepatic mRNA expressions of gluconeogenic genes of G6Pase and PEPCK by qPCR, (E). 
Western blot analysis of phosphorylation of JNK, p38, and eIF2 in liver fed with either 
HFHS or HFHS-R. Huh7 cells were pre-incubated with either DMSO or EA before 
stimulation with the mixture of glucose (Glc), fructose (Fr) and palmitate (PA) (F, G). (F) 
Phosphorylation of JNK, and p38 expression by western blot. (G) Phosphorylation of 
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IRS2 and Akt by western blot with and without insulin (100 nM) treatment. -actin was 
used for loading control. Data are expressed as mean ± SEM (n = 6). Bars with different 
letters are significantly different by one-way ANOVA. 
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Figure IV -4 RSF supplementation reduced hepatic oxidative stress against HS diet. 
Eight week-old male C57BL/6 mice were fed with HF (grey), HFHS (white), or HFHS-R 
(black) diet for 12 weeks (n=6 per group). (A) H2O2 level (mol/ mg protein) in liver 
sample. (B) Relative ROS production in huh 7 cells with or without EA using DCFDA 
florescence as molecular probe for detecting ROS production (Left). DCF fluorescence 
was visualized by fluorescence microscopy (Right). Data are expressed as mean ± SEMs. 
Bars with different letters are significantly different by one-way ANOVA.  
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Figure IV -5 RSF supplementation attenuated visceral adipocyte hypertrophy and 
adipose inflammation against HS diet. 
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Eight week-old male C57BL/6 mice were fed with HF, HFHS, or HFHS-R diet for 12 
weeks (n=6 per group). (A) Representative microscopic images of epididymal adipose 
tissue by H&E staining. Arrows indicate macrophage infiltration, (B) Average size 
(diameter) of epididymal adipocytes (n=6 mice per group), (C) Adipocyte size 
distribution, The line of best fit is shown (Gaussian curve fitting), (D) Plasma adiponectin 
levels (ng/mL) quantified by ELISA, (E) mRNA expression levels of adiponectin, IL-6, 
IL-8, F4/80, TNF and MCP1 in epididymal adipose tissue quantified by qPCR. (F) 
Immunofluorescent staining of F4/80 (Green). The nuclei counterstained by DAPI (Blue) 
and phase contrast images were overlapped. (G) Homogenized epididymal adipose tissue 
and plasma (pooled sample n=6 per group) from HFHS or HFHS-R fed mice were used 
for simultaneous detection of multiple inflammatory cytokines using mouse 
inflammatory array C1. Data are expressed as mean ± SEMs. Bars with different letters 
are significantly different by one-way ANOVA. **P< 0.01, ***P< 0.001 (HFHS vs. 
HFHF-R) by Student’s t-test. 
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Supplemental Table 1. Dietary composition of isocaloric HF diet, HFHS diet, and 
HFHS diet containing different ingredients fed to male C57BL/6J mice for 12 weeks
1
. 
Ingredients   
HF 
diet 
  
HFHS  
diet  
  
HFHS-R 
diet  
       
  
g/kg 
 
g/kg 
 
g/kg 
       Casein 
 
195 
 
195 
 
195 
L-Cystine 
 
3 
 
3 
 
3 
       
Sucrose 
 
0 
 
435 
 
435 
Corn Starch 
 
435 
 
0 
 
0 
Maltodextrin 
 
50 
 
50 
 
50 
       
Lard 
 
175 
 
175 
 
175 
Soybean oil 
 
39 
 
39 
 
39 
       
Cellulose 
 
40 
 
40 
 
10 
HPMC 
 
10 
 
10 
 
10 
Mineral Mix 
 
35 
 
35 
 
35 
Calcium 
Carbonate  
4 
 
4 
 
4 
Vitamin Mix 
 
10 
 
10 
 
10 
Choline 
bitartrate  
2 
 
2 
 
2 
RSF 
 
0 
 
0 
 
30 
Total  998  998  998 
       
  Kcal (%)  Kcal (%)  Kcal (%) 
Carbohydrate  42.2  42.2  42.2 
(Sucrose)  (0.0)  (37.0)  (37.0) 
Protein  16.9  16.9  16.9 
Fat  41.0  41.0  41.0 
Kcal/g  4.7  4.7  4.7 
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Supplemental Table 2. Primer sequences for qPCR 
Gene Forward/Reverse Sequence (5′-3’) 
mAdiponectin 
Forward ACAATGGCACACCAGGCCGT 
Reverse TGCCAGGGGTTCCGGGGAAG 
mChREBP 
Forward ATATCTCCGACACACTCTTCACC 
Reverse GTCAGGTCTGGCTGGATCATG 
mDAGT2 
Forward CCGCAAAGGCTTTGTGAAG 
Reverse GGAATAAGTGGGAACCAGATCA 
mF4/80 
Forward CTTTGGCTATGGGCTTCCAGTC 
Reverse GCAAGGAGGACAGAGTTTATCGTG 
mG6Pase 
Forward CGACTCGCTATCTCCAAGTGA 
Reverse GTTGAACCAGTCTCCGACCA 
mIL-6 
Forward CTGCAAGAGACTTCCATCCAGTT 
Reverse AGGGAAGGCCGTGGTTGT 
mIL-8 
Forward GGTCTGCTACGGGCTCACA 
Reverse CCCGGTGTTTCTGCCTCAT 
mLPL 
Forward CATCTCATTCCTGGATTAGCAGAC 
Reverse CCGATACAACCAGTCTACTACAATG 
mLXR 
Forward AACCTCAAGATGCAGGAGACC 
Reverse GACTCCAACCCTATCCCTAAAGC 
mMCP1 
Forward AGGTCCCTGTCATGCTTCTG 
Reverse GCTGCTGGTGATCCTCTTGT 
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mPEPCK 
Forward CTGCATAACGGTCTGGACTTC 
Reverse CAGCAACTGCCCGTACTCC 
mSCD-1 
Forward GGGACAGATATGGTGTGAAACTATG 
Reverse TTACAGACACTGCCCCTCAAC 
mSREBP1c 
Forward GTGAGCCTGACAAGCAATCA 
Reverse GGTGCCTACAGAGCAAGAGG 
mTNF 
Forward GGCTGCCCCGACTACGT 
Reverse 
ACTTTCTCCTGGTATGAGATAGCAA
AT 
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Supplemental Fig. 1. Changes in BW were monitored by weekly of all mice. 
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Supplemental Fig. 2. Kinetic productions of ROS were monitored by measuring 
fluorescence intensity up to 10 min in Huh7 cells. 
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Supplemental Fig. 3. (A) Hepatic LDLr gene expressions in HF, HFHS, and HFHS-R 
fed mice. (B) Plasma levels of apoA-I and apoB by western blot. 
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Abstract  
Scope: Urolithins (Uro) are ellagic acid (EA)-derived metabolites produced by gut 
microbes. There is a growing interest in the biological activities of Uro. Our aim was to 
evaluate the impacts of Uro on regulating triglyceride (TG) accumulation using primary 
cultures of human adipocytes. 
Methods and Results: UroA, B, C, D, and iso-UroA, were used to determine the effect 
of Uro on adipogenesis and lipogenesis. Individual Uro (30 M) were added to human 
adipogenic stem cells (hASCs) during differentiation. UroA, C and D, but not iso-UroA 
and UroB, significantly inhibited new fat cell formation by decreasing TG accumulation 
and adipogenic protein and gene expressions. The regulation of TG synthesis by Uro was 
investigated via metabolic chasing with radiolabeled precursors. UroA, C, and D 
attenuated the conversion of [
3
H]-acetate into [
3
H]-TG as well as [
14
C]-oleic acid (OA) 
into [
14
C]-TG, while increasing the conversion of [
3
H]-OA to [
3
H]-H2O (FA oxidation). 
Furthermore, UroC, D and A  promoted the phosphorylation of AMP-activated protein 
kinase (AMPK), implicating that Uro may alter energy-sensing metabolic pathways in 
primary human adipocytes.  
Conclusions: Taken together, our results demonstrated that UroA, C, and D reduce TG 
accumulation and increase FA oxidation via AMPK-associated mechanisms in primary 
cultures of human adipocytes. 
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1 Introduction 
Ellagitannins (ETs) and ellagic acid (EA) derivatives are naturally occurring 
polyphenols found in pomegranate, berries, and nuts. It has been reported that EA exerts 
various health benefits including free radical scavenger activity and anti-proliferative 
effects in various types of cancer in vivo and in vitro [1-3]. There is a substantial body of 
evidence that supplementation with pure EA alone or consumption of EA-enriched fruits 
and nuts attenuates body fat mass and liver lipids [4-6], suggesting that EA possesses 
lipid-lowering characteristics. Supporting this, our group has recently reported that EA 
reduces adipogenesis through the inhibition of co-activator arginine methyltransferase 1 
(CARM1) in primary human adipogenic stem cells (hASCs) [7], alters lipid mechanisms 
both in human adipocytes and hepatocytes [8], and normalizes high sugar-mediated 
metabolic dysfunction (under review).  
Likewise to many other health-promoting polyphenolic compounds, low 
bioavailability of EA remains paradoxical. Oral administration of pure EA or EA-
containing products in both rodents and humans showed that ~ 1 M of EA can be found 
in plasma or tissues [9, 10]. This is attributed to the fact that EA undergoes extensive 
metabolic transformation prior to absorption [11]. In the intestinal lumen, EA is 
extensively metabolized by gut microbes producing a series of metabolites called 
urolithins (Uro). Uro are characterized by a common 6H-dibenzo[b,d]-pyran-6-one 
nucleus and a decreasing number of phenolic hydroxyl groups (UroDUroC UroA or 
iso-UroAUroB) (Fig. 1A) [12]. Among Uro species, UroA is the major metabolite 
observed in humans while Iso-UroA and UroB conjugates are also observed in some, but 
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not all, humans. As the result of microbial actions, EA is converted into bioavailable Uro 
which can reach significant concentrations in plasma and tissues [12-15]. 
Recently, several studies have demonstrated that Uro have metabolic 
characteristics of EA showing anti-inflammatory [16], anti-cancer [17, 18], anti-glycative 
[19] and anti-oxidant [20] properties. However, it is largely unknown if Uro have TG-
lowering effects by altering lipid metabolism. To address this issue, we investigated the 
effects of individual Uro on lipid metabolism in human adipocytes and confirmed 
augmented fatty acid (FA) oxidation in human hepatoma Huh7 cells. Here, we are the 
first to report that Uro (30 M) possess biological activites to downregulate adipogenesis 
and lipogenesis similar to EA in human adipocytes. We also demonstrated that Uro alter 
lipid metabolism via AMPK activation.  
   
2 Materials and methods 
2.1 Chemical reagents 
 All cell culture supplies were purchased from Fisher Scientific. Fetal bovine 
serum (FBS) and penicillin-streptomycin were purchased from Cellgro Mediatech, Inc. 
(Herndon, VA). Rosiglitazone (BRL49653) was purchased from Cayman Chemical (Ann 
Arbor, MI). EA was purchased from Sigma-Aldrich (St. Louis, MO). UroA, B, C, D and 
iso-UroA were obtained as described elsewhere [21]. All other chemicals and reagents 
were purchased from Sigma Chemical Co (St. Louis, MO), unless otherwise stated. 
2.2 Cell culture 
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All protocols and procedures were approved by the Institutional Review Board at 
the University of Nebraska-Lincoln. For isolation of human adipogenic stem cells 
(hASCs), abdominal adipose tissue was obtained from females with a body mass index 
(BMI) of ~30 during liposuction or abdominal plastic surgeries. Isolation of hASCs and 
differentiation of adipocytes was conducted as we described previously [7, 8]. Each 
independent experiment was repeated at least three times using a pool of hASCs from 
three or four human subjects to avoid individual variation. Huh7 cells were maintained in 
Dulbecco’s modification of Eagle’s medium (DMEM) containing 1% L-glutamine, 10% 
fetal bovine serum, 100 units/ml penicillin, 100  g/ml streptomycin in 5% CO2 at 37°C. 
The medium was changed every 3 days. 
2.3 Cell viability assay 
 The cytotoxic effects of Uro and EA were determined using the XTT Cell 
Viability Kit (Cell Signaling Technology, Danvers, MA) according to the manufacturer’s 
protocol. Briefly, undifferentiated hASCs, fully differentiated hASCs, and Huh7 cells 
were cultured in 96-well plates using a seeding density of ~20,000 cells per well. Cells 
were incubated with either dimethyl sulfoxide (DMSO) or increasing concentrations of 
Uro and EA for 24 hours (Fig. 2, 5). Culture medium was then replaced with fresh 
medium containing XTT solution for 3 hours at 37℃ before measurement of OD 450 nm 
using a Synergy™ H1 hybrid plate reader (BioTek, Winooski, VT). 
2.4 Lipid accumulation  
To measure the lipid accumulation in human adipocytes, cells were fixed with 10% 
formalin and stained with Oil Red O (ORO). Bright field images were taken by EVOS® 
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XL microscope (AMG), or ORO dye was extracted by isopropanol to quantify relative 
TG accumulation (at OD 500 nm). 
2.5 [14C]-oleic acid (OA) and [3H]-acetate incorporation into FA and TG 
The measurement of TG esterification rate and de novo lipid synthesis in cultures 
of mature adipocytes or human hepatoma Huh7 cells was conducted as described 
previously [8]. Briefly, cells were incubated with serum-free low glucose (1,000 mg/L d-
(+)-glucose) overnight before the experiment. [14C]-OA (final concentration of 0.5 
μCi/mL, Perkin Elmer) and [3H]-acetate (final concentration of 0.5 μCi/mL, Perkin 
Elmer) were mixed with conditioned media or sodium oleate (Sigma)-Bovine Serum 
Albumin (BSA, fatty acid free, Sigma) complex, then added to cells for 3 hours. After 3 
hours incubation with [14C]-OA and [3H]-acetate, medium (containing unincorporated 
isotope) was removed by washing with phosphate-buffered saline (PBS). Cellular lipids 
were extracted using the Bligh and Dyer method [22]. Next, thin layer chromatography 
was performed to fractionate FA and TG, and the [14C] and [3H] radioactivity was 
measured by liquid scintillation counting (Tri-Carb 2000TR, Packard). Radioactivity was 
normalized by protein concentration quantified by bicinchoninic acid (BCA) colorimetric 
assay (Pierce, Rockford, IL).  
2.6 Fatty acid oxidation rate using [3H]-OA 
To measure the FA oxidation rate in cultures of mature adipocytes or human 
hepatoma Huh7 cells, we followed previously published methods [23]. Briefly, cells were 
incubated with serum-free low glucose (1,000 mg/L d-(+)-glucose) before the experiment. 
[3H]-OA (final concentration of 0.5 μCi/mL, Perkin Elmer) was mixed with sodium 
oleate-BSA complex, and then added to cells for 2 hours. [3H] radioactive containing 
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medium was harvested, and precipitated using trichloroacetic acid (TCA) solution. After 
precipitation, 6N NaOH was added to reach a final concentration of 0.8-1.0N, resulting in 
an alkaline supernatant. Next, supernatant was put through columns filled with Dowex™ 
ion-exchange resin (ACROS Organics™) to capture [3H]-H2O. Finally, radioactivity was 
measured by liquid scintillation counting. 
2.7 qPCR  
Gene-specific primers for qPCR were obtained from Integrated DNA 
Technologies (Chicago, IL). Total RNA was isolated using TRIzol® reagent (Invitrogen). 
To remove any potential genomic DNA contamination, mRNA was treated with DNase 
(iScript™ cDNA Synthesis Kit, Bio-Rad). Gene expression was determined by real-time 
qPCR (ABI7300, Applied Biosystems), and relative gene expression was normalized by 
36B4 (primer sequences available in Supplemental Table 1).  
2.8 Western blot analysis 
To prepare total cell lysates, monolayers of hASC cultures and fully differentiated 
adipocytes were scraped with ice cold radioimmune precipitation assay (RIPA) buffer 
(Thermo Scientific) containing protease inhibitors (Sigma) and phosphatase inhibitors (2 
mM Na3VO4, 20 mM β-glycerophosphate and 10 mM NaF). Proteins were fractionated 
using 8 or 10% SDS-PAGE, transferred to PVDF membranes, and incubated with the 
relevant antibodies. Chemiluminescence from ECL (Western Lightning) solution was 
detected using a FluorChem E Imaging System (Cell Biosciences). Polyclonal or 
monoclonal antibodies targeting phospho- AMP-activated protein kinase (AMPK) 
(Ser473, #4060), total AMPK (#9279), CCAAT/enhancer binding protein  (C/EBP 
135 
 
 
 
(#2295), fatty acid synthase (Fas) (#3180), and β-actin (#4967) were purchased from Cell 
Signaling Technology. The mouse monoclonal antibodies for fatty acid binding protein 4 
(aP2) (sc-271529) and PPAR (sc-7273) were purchased from Santa Cruz Biotechnology 
(Dallas, TX).  
2.9 Statistical analysis 
Results are presented as means ± SEM. The data were statistically analyzed using 
one-way ANOVA with Tukey’s multiple comparison tests. All analyses were performed 
with GraphPad Prism 5 (Version 5.04).   
  
3 Results 
3.1. Urolithins do not affect the viability of primary human adipogenic stem cells 
(hASCs) at concentrations of 0-30 M  
Currently, it is unknown whether Uro affect the cell viability of human adipocytes. 
To address this question, cytotoxic effects of individual Uro were determined both in 
undifferentiated hASCs and fully differentiated adipocytes. UroA, B, C, D, iso-UroA and 
EA were incubated with either hASCs or mature adipocytes for 24 hours before XTT 
assay. Similar to EA, Uro treatment slightly affected cell bioavailability (~80%) but no 
specific cytotoxic effects were observed in up to 30 M concentrations (Fig. 1B-G). 
Based on these results, for the remaining experiments we used the 30 M of Uro in order 
to augment the potential action but without causing cellular damage.  
3.2 Urolithins inhibit adipogenesis in hASCs 
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We previously demonstrated that EA suppressed adipogenic differentiation in 
hASCs [7, 8]. To determine whether Uro were abl
individual Uro was added to hASCs during differentiation (Fig. 2A). The presence of Uro, 
but not iso-UroA, caused a significant reduction of TG accumulation measured by ORO 
staining (Fig. 2A, B). The rank order of anti-adipogenic potential was UroA, C, D >> 
UroB > iso-UroA as assessed by TG accumulation using ORO staining. To further 
confirm the anti-adipogenic effects of Uro, adipogenic gene and protein expression levels 
were determined by qPCR and Western blot. Consistent with reduced TG accumulation, 
Uro treatment, except for iso-UroA, significantly suppressed adipogenic gene expression 
including PPAR and Fas (Fig. 2C). Adipogenic protein expression including aP2, Fas, 
PPAR, and C/EBP were also dramatically reduced in cultures treated with UroC and D 
and to a lesser magnitude with iso-UroA (Fig. 2D). To gain insight into whether Uro alter 
epigenetic marks similar to their parent compound EA [7], histone 3 arginine 17 
methylation (H3R17me2), and histone acetylation (AcH3) levels were examined. 
Interestingly, only UroC incubation, but no other Uro treatment, markedly suppressed the 
epigenetic markers (Supplemental Fig. 1).  
Several phytochemicals are known to inhibit adipogenesis through the mechanism 
related to AMPK activation [24-27]. AMPK is a major energy-sensor triggering a variety 
of catabolic processes and suppressing anabolic pathways simultaneously [28]. Treatment 
with EA increased AMPK phosphorylation dose-dependently (Fig. 2E). To further 
identify whether Uro are also able to regulate AMPK activation, we examined 
phosphorylated and total AMPK levels. Interestingly, UroA, C, and D increased 
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phosphorylated AMPK levels (Fig. 2F), which is consistent with the trend of the anti-
adipogenic role of Uro. 
3.3 Urolithins attenuate lipid accumulation in cultures of human adipocytes  
Next, we asked whether Uro could antagonize adipocyte hypertrophy. To examine 
this, fully differentiated cultures of human adipocytes were exposed to Uro for seven 
days based on the experimental design (Fig. 3A, upper). Exposure to 30 M Uro for 
seven days caused a significant reduction of TG accumulation, but not UroB and iso-
UroA, as measured by ORO staining (Fig. 3A, below). To test whether the reduction of 
TG accumulation was aligned with lipogenic transcriptional inhibition, we measured 
mRNA expressions. Uro treatment (A, C, and D) decreased lipogenic-specific gene 
-CoA 
desaturase-1 (SCD-1) compared to vehicle control (Fig. 3B). UroC and D are potent EA-
derived metabolites in upregulating AMPK activation in fully differentiated adipocytes 
(Fig. 3C).  
3.4 Urolithins regulate lipid metabolisms in cultures of human adipocytes 
We then investigated whether lipid-lowering effects of Uro are due to an 
alteration of lipogenic pathways. Fully differentiated adipocytes were incubated with 
radioactive precursors of [3H]-acetate and [14C]-OA to measure their conversion into 
[3H]-TG (de novo synthesis of TG) and [14C]-TG (esterification of TG). The conversion 
of [3H]-acetate into [3H]-TG was significantly dampened in UroA and UroD treated 
adipocytes (Fig. 4A). Consistently, UroA and D incubation was associated with a 
significant decrease of conversion of [14C]-OA into [14C]-TG, indicating a decrease of 
TG esterification by UroA and D (Fig. 4B). To determine whether FA oxidation is 
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involved in lipid-lowering effects of Uro, we measured FA oxidation rate in Uro-treated 
adipocytes. FA oxidation by determining [3H]-H2O release from [3H]-OA clearly 
showed that UroA, C, and D markedly increased FA oxidation, but not in iso-UroA and 
UroB treated adipocytes (Fig. 4C). Taken together, these data implicate that the inhibition 
of de novo synthesis of TG and FA esterification are accompanied by transcriptional 
regulation of lipogenic gene expression in Uro-treated human adipocytes.   
3.5 Urolithins regulate lipid metabolism in Huh7 cells  
We further examined the effects of Uro on TG esterification, de novo synthesis 
and FA oxidation in human hepatoma Huh7 cells. Prior to analysis of lipid metabolism, 
we first measured the cytotoxic effects of individual Uro in Huh7 cells. The 
concentrations (0-30 M) of UroA, B, C, D, iso-UroA and EA treatment slightly affected 
cell bioavailability (~80%) but no specific cytotoxic effects were observed in up to 30 
M concentrations (Fig. 5A). Next, to test whether Uro alter the lipogenic pathways, 
radiolabeled precursors were incubated with Huh7 cells, as with human adipocytes. 
Incorporation of [3H]-acetate into [3H]-FA and [3H]-TG were markedly decreased with 
UroC and D (Fig. 5B and C). Conversion of [14C]-OA into [14C]-TG was clearly 
inhibited by UroC treatment (Fig. 5D). FA oxidation rate was increased by UroA and C 
treated Huh7 cells, which was confirmed by [3H]-H2O release from [3H]-OA (Fig. 5E).  
  
4 Discussion 
Uro are gut microbiota-derived metabolites of EA and ETs. Different types of Uro 
(Fig. 1A) are produced by intestinal microbes, which may reflect the metabolic health 
status of hosts [29]. Although it has long been known that Uro may be critical 
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determinants of the effectiveness of EA supplementation, it is largely unknown whether 
different species of Uro possess different biological activities in humans. Recently, a 
number of studies have reported the unique role of Uro species by evaluating their 
efficacy in various cancer [17, 30], and inflammatory diseases [16, 31]. One recent study 
[29] and other unpublished observation correlate a higher prevalence of the metabotype 
producing iso-UroA and UroB in overweight and obese individuals, while UroA is 
associated with healthy individuals. However, no studies have been conducted to 
determine the function of individual Uro in human obesity. The present study was 
specifically designed to assess the role of individual Uro species in manipulating lipid 
metabolism using primary human adipocytes. Here we demonstrated that UroA, C and D 
are effective in attenuating TG accumulation and increasing FA oxidation through 
AMPK-dependent mechanisms in primary human adipocytes as well as in Huh7 cells. 
These results may provide a novel insight into a ‘structure and function’ relationship 
among Uro, which may lead to a unique therapeutic design to control adiposity.   
An accumulating body of evidence suggests that the gut microbial community 
affects the host’s energy homeostasis by altering energy metabolism [32-34]. To 
corroborate this concept, production of different Uro may comprise a part of the 
mechanism in which gut microbes regulate the host’s energy metabolism. In other words, 
metabolically healthy subjects may possess microbiota that are able to generate mainly 
active Uro such as UroA (i.e. subjects belonging to the so-called ‘metabotype A’ [29]). In 
contrast, metabolically unhealthy humans may have bacterial communities producing 
UroA but also other less active urolithins such as  iso-UroA and UroB (i.e., subjects with 
‘metabotype B’ [29]). García-Villalba et al. reported that there were compositional 
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differences in the gut microbiome between human subjects who produce UroA (effective 
Uro) and who produce iso-UroA and B (less active Uro) [11]. Also, subjects who have a 
higher risk of chronic illness produce iso-UroA and UroB [29], the two inactive EA 
metabolites in our experimental setting (Fig. 2-4). Recently, Gordonibacter 
urolithinfaciens sp. nov. has been identified as a novel bacterial species responsible for 
converting EA into UroM5 and UroC [35]. This bacterium belongs to the family 
Coriobacteriaceae a family that is associated with benefits in obesity [36]. Since the 
bacterial phylum that specifically transform EA or its intermediate metabolites into UroA 
vs. iso-UroA/UroB have not yet been identified, it could be of interest for future studies.  
Numerous studies in animals and humans have demonstrated that free EA can be 
found in no more than 100 nM concentrations after oral administration of EA or ET-
containing foods [9, 10]. The low bioavailability of EA is largely due to limited solubility 
and its rapid metabolism into Uro by the gut microbiome [10]. As a metabolic 
consequence, Uro can reach relevant concentrations in the blood stream and human colon 
microenvironment [12, 13]. Although Uro might not be accumulated in metabolic tissues, 
i.e., adipose tissue, liver or muscle, a few reports have shown that Uro are able to 
circulate enterohepatically [37]. In terms of cytotoxicity, 50-150 M of Uro have 
exhibited anti-cancer properties by inhibiting cell proliferation and cell cycle progression 
in various carcinoma cell lines [17, 38]. In this study, we first assessed the cytotoxicity of 
Uro treatment does not seem to affect cell viability in non-carcinogenic cells [31], 
implying that Uro might induce apoptosis in malignant tumor cells but not in 
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treatments showed no sign of cytotoxicity in time frames of both early- and terminal-
stages of adipogenesis. The anti-adipogenic and anti-lipogenic effects of Uro in our study 
were not due to the apoptotic property of Uro (Fig. 1B-G). Thus, we regarded 30 M of 
Uro as a non-toxic concentration to assess potency of individual Uro in regulating lipid 
metabolism in human adipocytes. In our study, Uro treatment in adipocytes was 
associated with at least three metabolic outcomes: 1) attenuating adipogenesis, 2) 
inhibiting TG accumulation, and 3) increasing AMPK activation. 
The major distinctive metabolic consequences that we immediately noticed was 
that Uro differentially impacted adipogenesis in hASCs. UroA, C and D treatment, but 
not iso-UroA or UroB, interfered with adipogenic differentiation (Fig. 2). Recently, 
estrogen receptor  (ER) has been proposed as a negative regulator of adipocyte 
development in preadipocytes [39]. Interestingly, Larrosa et al. showed that UroA 
possesses higher ER binding affinity than UroB in breast cancer cells suggesting that 
UroA plays a role as a phytoestrogen (ER binding affinity of UroA:  > ) [40]. In terms 
of structural differences, EA, UroA, C and D have common hydroxyl position at number 
8 carbon (-OH at C8) compared to iso-UroA or UroB. González-Sarrías et al. also 
proposed that phase II phenolic enzymatic activities are crucially affected by reactive 
moieties such as hydroxyl groups [17]. This interpretation aligns with our results showing 
that the absence of -OH moiety at C8 position of Uro, due to isomerism (iso-UroA) or 
metabolic loss (UroB) is inversely correlated with the ability to downregulate adipogenic 
differentiation. Thus, it may also be reasonable to assume that -OH moiety at C8 position 
might affect binding affinity to ER. Further studies are necessary to validate the 
aforementioned structure-function relationship in adipogenic differentiation. The other 
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possible mechanism of Uro’s anti-adipogenic effect could be explained by its ability to 
alter epigenetic marks. We have previously shown that EA modified histone 
methyltransferase (CARM1) enzyme activities during adipogenesis [7]. Consistently, we 
were able to observe that UroC downregulated histone arginine 17 methylation during 
adipogenesis (Supplemental Fig. 1). UroC was also reported to reduce TNF-induced 
inflammation through inhibition of histone acetyltransferase (HAT) activity in the 
monocyte cell [41]. At this point, we speculate UroC may have stronger DNA binding 
affinity comparable to EA [42, 43] than the other Uro intermediates, conferring ability to 
edit epigenetic codes such as histone methylation and/or acetylation. Collectively, 
differential regulation of adipogenesis by Uro likely originates from their structural 
difference of Uro. Future studies are required to scrutinize the metabolic contribution of 
C8 hydroxyl moiety of Uro to ER binding affinity, CARM1 activity, and AMPK 
activation.   
Subsequently, we examined the potential role of Uro in regulating lipid 
metabolism in fully differentiated adipocytes and hepatoma Huh7 cells. Previously, we 
showed that EA modulates global lipid metabolism by attenuating TG accumulation in 
both adipocytes and hepatocytes [8]. This TG-lowering effect seems to be conserved in 
mammalian cells [8] and even in yeasts (data not shown). In this current research setting, 
we found that Uro effectively reduced de novo synthesis and TG esterification and 
enhanced FA oxidation in adipocytes (Fig. 3, 4). These data revealed that EA apparently 
gradually lost its ability to downregulate lipid accumulation while EA is successively 
metabolized by gut microbes until its conversion to the least effective UroB. Therefore, 
the potency of Uro in regulating TG metabolism could be ranked as earlier metabolites 
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(UroC and D) > intermediate metabolite (UroA) > later metabolite (UroB). Agreeing to 
the fact that EA shows a global impact in lowering lipids in various cells, Uro were also 
effective in attenuating TG accumulation in Huh7 cells (Fig. 5). The simultaneous lipid-
lowering action in both adipocytes and hepatocytes is one of the ultimate goals for weight 
loss as dietary intervention agents. To accomplish this goal, upregulation of FA oxidation 
is critical; otherwise the failure of FA accumulation in adipose tissue triggers lipotoxicity 
and hepatic steatosis. It is interesting that UroC was more potent in modulating TG 
accumulation than UroD in hepatocytes. More noticeably, UroA, C and D significantly 
elevated FA oxidation ([3H]-OA[3H]-H2O) in hepatocytes, satisfying the criteria for 
effective dietary supplementation to mitigate lipid accumulation both in adipocytes and 
hepatocytes. Further studies should be conducted to determine the efficacy of UroC, D 
and A in vivo.   
Lastly, we have found AMPK activation could be a link mediating anti-
adipogenic and anti-lipogenic effects of Uro. AMPK is an energy sensor that shuts down 
anabolic pathways [44]. Phosphorylation of AMPK inhibits transcriptional activation for 
adipogenesis, TG synthesis, and FA oxidation [45]. Here, we showed EA promotes 
AMPK activation during adipogenesis of hASC (Fig. 2E); Wang et al. also showed the 
implication of AMPK activation by EA in 3T3-L1 cells [46]. Consistently, our results 
showed that upregulation of AMPK phosphorylation by UroA, C, and D attenuated: i) 
adipogenesis (Fig. 2); ii) de novo lipogenesis (gene expressions and metabolic conversion 
of radiolabeled precursors) and TG esterification (Fig. 3, 4, 5); and iii) FA oxidation (Fig. 
4, 5). Our in vivo data also supports that ET-containing raspberry seed flour 
supplementation promotes AMPK activation in adipose tissue against high fat and high 
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sugar fed C57BL/6 mice (under review), thereby leading to attenuation of adiposity. 
Consistently, the recent animal study showed that punicalagin (ET)-enriched 
pomegranate consumption prevents obesity associated-cardiac metabolic disorders 
through AMPK activation [47]. The regulation of AMPK by the structural specificity of 
EA and Uro will be of interest for future study to further elucidate the ultimate role of EA 
in regulating lipid metabolism. 
In our study, we revealed the previously unknown function of Uro, gut 
metabolites of EA, as potential regulators of lipid metabolism in adipocytes. We also 
compared whether individual Uro could exert a differential impact on lipogenesis and FA 
oxidation in adipocytes and hepatocytes. We identified that UroA, C, and D are more 
plausible to reduce TG accumulation, but not iso-UroA and UroB. Whether the 
differential impact of Uro in lipid metabolism is dictated by structural differences of Uro, 
and these initial findings in vitro will be confirmed in vivo, must await future studies. 
Also, following studies should define whether the mode of action from the tentative 
mixtures of Uro (that are pertinent to human physiology) would be additive, synergistic 
and/or counteractive. Nevertheless, we believe that our study sheds new insight into Uro, 
gut metabolites of EA, as new dietary strategies to attenuate adiposity by activation of 
AMPK. 
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Figure V -1 Metabolism of EA to produce Uro and the effects of Uro on cell viability 
in primary human adipocytes. 
 (A) Microbial enzymatic transformation to produce a series of Uro metabolites from EA. 
Chemical structures of test compounds are shown. Culture of hASCs containing 
undifferentiated and differentiated cells were treated with either 10M EA (B) or 30 M 
UroA (C), iso-Uro A (D), UroB (E), UroC (F), and UroD (G) for 24 hours. XTT reagent 
was added 3 hours before measurement of OD 450nm. Data are expressed as a 
percentage of the vehicle control (DMSO). Each data point represents the mean ± S.E.M 
(n=3).  
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Figure V -2 Uro, but not iso-UroA, suppressed adipogenesis in hASCs. 
 (A, upper) Experimental Scheme: hASCs were seeded the day before differentiation (d0). 
Cultures of hASCs were induced to differentiation (d1*) in the presence of either DMSO 
visualized by Oil Red O staining and representative images from three separate 
experiments are shown. (B) Extracted staining was quantified (OD 500 nm) and relative 
TG accumulations to the DMSO control are shown. (C) Adipogenic gene expression of 
PPAR, and Fas by qPCR. (D) Adipogenic protein expressions of aP2, Fas, PPAR, and 
C/EBP by Western blot analysis. (E) Culture of hASCs was differentiated for 2 days in 
the presence or absence of 0, 4, and 8 M EA. Total cell extracts were immunoblotted 
with phosphor or total antibodies targeting AMPK. (F) Immunoblot of phosphor or total 
antibodies targeting AMPK in Uro treated hASCs. All values are presented as the mean 
±S.E.M. Bars with different letters are significantly different by one-way ANOVA. 
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Figure V -3 Uro, but not iso-UroA, suppressed lipogenesis in mature human 
adipocytes. 
148 
 
 
 
 (A, upper) Experimental Scheme: hASCs were seeded the day before differentiation (d0) 
and induced to differentiation (d1*). hASCs were kept differentiated into fully 
differentiated adipocytes until d10. 30 M Uro was added to the fully differentiated 
human adipocytes (d10) and incubated for 7 days. (A, below) Relative TG accumulations 
stained by Oil Red O. (B) Relative gene expressions levels of PPAR, Fas, ATGL and 
SCD1 by qPCR. (C) Cultures of fully differentiated adipocytes were treated with 30 M 
Uro for 3 days. Total cell extracts were immunoblotted with phosphor or total antibodies 
targeting AMPK. All values are presented as the mean ±S.E.M. Bars with different letters 
are significantly different by one-way ANOVA. 
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Figure V -4 Uro regulated lipid 
metabolisms in human adipocytes. 
Uro (30 M) was added to the differentiated 
human adipocytes (d10) and incubated for 3 
days.  
(A) Conversion of [
3
H]-acetate into [
3
H]-TG. 
(B) Conversion of [
14
C]-OA into [
14
C]-TG. 
(C) [
3
H]-OA into [
3
H]-H2O. All values are 
presented as the mean ±S.E.M. Bars with 
different letters are significantly different by 
one-way ANOVA. 
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Figure V -5 Uro, but not iso-UroA, regulated lipid mechanisms in human hepatoma 
Huh7 cells. 
 (A) Cultures of Huh7 cells were treated with either 10M EA or 30 M UroA, iso-Uro 
A, UroB, UroC, and UroD for 24 hours. XTT reagent was added 3 hours before 
151 
 
 
 
measurement of OD 450nm. Huh7 cells were pre-incubated with Uro (30 M) for 48 
hours and 0.4 or 0.8 mM BSA-OA complex was loaded for 3 hours with radiolabeled 
precursors ([
3
H]-acetate, [
14
C]-OA, [
3
H]-OA). (B) Conversion of [
3
H]-acetate into [
3
H]-
FA. (C) Conversion of [
3
H]-acetate into [
3
H]-TG. (D) Conversion of [
14
C]-OA into [
14
C]-
TG. (E) Conversion of [
3
H]-OA into [
3
H]-H2O. All values are presented as the mean 
±S.E.M. Bars with different letters are significantly different by one-way ANOVA.   
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Supplemental Fig. 1. Cultures of hASCs were induced to differentiation (d1) in the 
presence of either DMSO (vehicle control) or 30 M Uro for 10 days. Nuclear extracts 
from Uro treated hASCs were immunoblotted for histone modification enzyme 
(H3R17me2, AcH3, and PPAR). 
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Supporting Information 
Supplemental Table 1. Primer sequences for qPCR 
Gene Forward/Reverse Sequence (5′-3’) 
h36B4 
Forward GAAGGCTGTGGTGCTGATG 
Reverse GTGAGGTCCTCCTTGGTGAA 
hATGL 
Forward CTGACCACCCTCTCCAACAT 
Reverse ACCAGGTACTGGCAGATGCT 
hFas 
Forward GGCAAGCTGAAGGACCTGTCTA 
Reverse AATCTGGGTTGATGCCTCCGT 
hPPAR 
Forward TGCTGTTATGGGTGAAACTCTG 
Reverse TCAAAGGAGTGGGAGTGGTC 
hSCD1 
Forward GGGTGAGGGCTTCCACAACTA 
Reverse CGGCCATGCAATCAATGAA 
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Supporting Information 
Supplemental Table 1. Primer sequences for qPCR 
Gene Forward/Reverse Sequence (5′-3’) 
h36B4 
Forward GAAGGCTGTGGTGCTGATG 
Reverse GTGAGGTCCTCCTTGGTGAA 
hATGL 
Forward CTGACCACCCTCTCCAACAT 
Reverse ACCAGGTACTGGCAGATGCT 
hFas 
Forward GGCAAGCTGAAGGACCTGTCTA 
Reverse AATCTGGGTTGATGCCTCCGT 
hPPAR 
Forward TGCTGTTATGGGTGAAACTCTG 
Reverse TCAAAGGAGTGGGAGTGGTC 
hSCD1 
Forward GGGTGAGGGCTTCCACAACTA 
Reverse CGGCCATGCAATCAATGAA 
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OUTLOOK 
The results indicated that 10 M of EA inhibits adipogenic conversion as well as 
hypertrophic lipid accumulation in hASCs. Distinctive mechanisms are involved for 
reduction of lipid accumulation by EA in adipocytes. 1) During adipogenesis, EA 
reduced CARM1 activity results in a decrease of H3R17me2 levels, which may interrupt 
consecutive histone remodeling steps for adipocyte differentiation including histone 
acetylation and HDAC9 dissociation from chromatin. 2) During the mature stage of 
adipogenesis, EA reduced TG levels, glucose uptake and conversion of acetyl CoA to TG, 
but no significant impact on FA uptake or FA conversion to TG. Consistently, EA 
reduced TG contents in Huh7 hepatoma cells, which was accompanied by reduction of 
FA uptake, FA esterification into TG, de novo synthesis of TG as well as augmentation of 
FA oxidation. These lipid-lowering effects of EA in vitro were further confirmed in vivo 
by using C57BL6/J mice. EA supplementation by RSF (3% in diet) significantly reduced 
HFHS diet-induced body weight gain and dyslipidemia and improved insulin resistance. 
Furthermore, EA supplementation ameliorated fructose-induced hepatic toxicity through 
inhibition of ER/oxidative stress, which indirectly attenuated adipose/systemic 
inflammation. Lastly, we found the evidence that gut microbiota-derived metabolites, 
Uro, might resemble anti-adipogenic/lipogenic effects of EA. UroA, C, and D were 
biologically active metabolites to reduce lipid accumulation in both adipocyte and 
hepatocytes, which was comparable with EA treatment. Overall, these data suggested that 
EA is a potent dietary factor to attenuating obesity and Uro may be used as novel 
metabolites mediating EA’s effects on obesity and metabolic disorders. 
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These outcomes describe the association between EA treatment/ intake and 
outcomes in reducing obesity and obesity-associated complications. Mechanistic studies 
should be conducted to investigate EA’s anti-obesity effect. Secondly, dose-reponse 
studies in animal studies will be needed to determine the efficacy and safety ranges of EA 
dose. Determination of tissue distribution and plasma peak concentration of EA and EA-
metabolites after consumption of EA will be informative. As emerging evidence indicates 
that Uro may potentiate or nullify the health benefits of EA, the health beneficial results 
of EA will be compared between control conventional mice and germ-free mice and/or 
anti-biotic treated model (no Uro produced group).  This experiment is also significant in 
defining a potential role of gut microbiome ecology in lipid metabolisms. Regarding 
epigenetic regulation, as CARM1 is a key regulator to control adipogenesis by EA in 
adipose tissue, determine the adipose tissue-specific role of CARM1 in obesity-related 
disease would be of interest. Lastly, for practical applications the effects of EA 
fortification on the physical and chemical properties of the food products should be 
determined. 
 
 
 
